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Abstract   
  
Purpose: Rooibos (RB) has been reported to confer cardioprotection, but the underlying 
mechanisms are not fully elucidated. Furthermore, RB has never been tested against cardiac 
hypertrophy and apoptosis. Therefore, this study investigated the efficacy and underlying 
mechanisms of RB-induced cardioprotection in a model of angiotensin-II (Ang-II) induced 
cardiomyocyte hypertrophy & apoptosis.  
  
Methods: Six groups of H9c2 cardiomyoblasts were either exposed to 2% FBS supplemented  
DMEM (control), Ang-II (20µM), RB (100µg/ml), Losartan (10µM) and co-treatment with RB 
+ Ang-II or Ang-II + Losartan for 48 hrs. Cell viability, ATP levels, and hypertrophy and 
apoptosis signalling were measured with Western blotting. Cell size and mitochondrial 
membrane potential were measured using JC-1. Mitochondrial oxidative stress was measured 
with aconitase assay.  
  
Results: Ang-II induced hypertrophy as well as apoptosis in H9c2 cardiomyoblasts by 
increasing cell size and upregulating growth signalling pathways, while decreasing cell 
viability, up-regulating of pro-apoptotic markers (Bax and cleaved caspase-3) and 
downregulating anti-apoptotic Bcl-2.  In addition, Ang-II decreased mitochondrial membrane 
potential and ATP levels. RB co-treatment effectively antagonized Ang-II-induced 
hypertrophy and apoptosis of H9c2 cells. This was mediated by reducing cell size and 
dephosphorylating growth signalling pathways such as ERK 1/2, PKB, mTOR, Calcineurin and 
GSK-3ß.  RB also increased cell viability by increasing Bcl-2, decreasing Bax and cleaved 
caspase-3 and thereby, inhibiting apoptosis. The administration of RB prevented depolarization 
of mitochondrial membrane potential and increased ATP activity. RB also enhanced the 
expression of mitochondrial respiratory chain complex IV and V, probably through the 
enhancement of mitochondrial biogenesis and the electron transfer system.   
  
Conclusion: To our knowledge, the current study is the first to show that RB attenuates Ang-II 
induced cardiomyoblast hypertrophy and apoptosis by improving mitochondrial parameters 





   iv 
    
Opsomming  
  
Doel: Daar word berig dat Rooibos (RB) kardiobeskerming verleen, maar die onderliggende 
meganismes is nog nie volledig toegelig nie. Verder is RB nog nooit getoets in kardiale 
hipertrofie en apoptose nie. Daarom het hierdie studie die doeltreffendheid en onderliggende 
meganismes van RB-geïnduseerde kardiobeskerming in 'n model van angiotensien-II (Ang-II) 
geïnduseerde kardiomiosiet-hipertrofie en -apoptose ondersoek.  
  
Metodes: Ses groepe H9c2-kardiomioblaste is blootgestel aan 2% FBS aangevulde DMEM 
(kontrole), Ang-II (20 µM), RB (100 µg / ml), Losartan (10 µM) en gesamentlike behandeling 
met RB + Ang-II of Ang- II + Losartan vir 48 uur. Sellewensvatbaarheid, ATP-vlakke en 
hipertrofie en apoptose-sein is gemeet met Western blotting. Selgrootte en mitochondriale 
membraanpotensiaal is met behulp van JC-1 gemeet. Mitochondriale oksidatiewe stres is 
gemeet met akonitase-assai.  
  
Resultate: Ang-II ïnduseerd hipertrofie sowel as apoptose in H9c2-kardiomyoblaste deur die 
selgrootte te verhoog en die groei van seinpaaie op te reguleer, terwyl dit die lewensvatbaarheid 
van die selle verminder, die pro-apoptotiese merkers (Bax en gekliefde caspase-3) opreguleer 
en die anti-apoptotiese Bcl-2 afreguleer. Verder het Ang-II die mitochondriale 
membraanpotensiaal en ATP-vlakke verlaag.  Medebehandeling met RB het Ang-II- 
geïnduseerde hipertrofie en apoptose van H9c2-selle effektief geantagoniseer. Dit is bemiddel 
deur die vermindering van die selgrootte en die defosforilering van seinpaaie vir groei soos 
ERK 1/2, PKB, mTOR, Calcineurin en GSK-3ß. RB het ook die lewensvatbaarheid van die 
selle verhoog deur Bcl-2 te verhoog, Bax en gekliefde caspase-3 te verminder en dus apoptose 
te inhibeer. Die toediening van RB het depolarisasie van mitochondriale membraanpotensiaal 
voorkom en ATP-aktiwiteit verhoog. RB het ook die uitdrukking van mitochondriale 
respiratoriese kettingkompleks IV en V verbeter, waarskynlik deur die verbetering van 
mitochondriale biogenese en die elektronoordragstelsel.  
  
Gevolgtrekking: Na ons mening is die huidige studie die eerste om aan te toon dat RB Ang-II 
geïnduseerde kardiomioblast hipertrofie en apoptose attenueer/onderdruk, deur mitochondriale 
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Chapter 1: Literature review  
1.1 Introduction  
1.1.1 Cardiovascular diseases   
  
Cardiovascular diseases (CVDs) have been a leading cause of morbidity and mortality in 
modern nations for more than half a century (Quindry and Franklin, 2018; Maarman et al., 
2020). In 2015, CVDs were responsible for an estimated 17.7 million deaths, 31% was number 
of deaths globally (WHO, 2013). Moreover, 7.4 million of these deaths were attributed to 
coronary heart disease, while 9.2% occurred in the African region (Kengne et al., 2005). Out 
of the 17 million global deaths in 2017, an alarming 82% of deaths were in low and middle-
income countries (WHO, 2017). It is proposed that by 2030, the number of deaths attributable 
to CVD, will rise from 17 to 25 million (Kengne et al., 2005; WHO, 2012). It has further been 
reported that CVD are accountable for most of South African deaths compared to all cancers 
put together (Byrne et al., 2016). Thus, CVDs is a considerable health threat across the world, 
and increasingly so in countries like South Africa.   
  
CVDs include a number of conditions that cause a disruption in either the structure or function 
of the cardiovascular system, and some of these conditions can either be due to genetic or 
lifestyle factors (e.g. diet and physical activity) (Zafar, 2015). CVDs can be classified into 
different categories including rheumatic heart disease (RHD), congenital heart defects, 
hypertensive heart disease (HHD), inflammatory heart disease, and ischemic heart disease 
(IHD) (Figure 1). A large proportion of CVDs have been attributed to atherosclerosis, and 
includes conditions like coronary artery disease and acute myocardial ischemia (World Heart 
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Figure 1: The statistical prevalence of CVD distribution among man and women. (copied 
from The Heart and Stroke Foundation South Africa, 2016).  
  
1.1.2 Categories of heart disease  
1.1.2.1 Rheumatic heart disease  
  
RHD is known as cardiac damage that occurs over a long period of time due to either one severe 
incident or several recurring incidents of acute rheumatic fever (ARF) (Bertrand et al., 1988). 
It remains a critical cause of morbidity or mortality globally, notably in resource poorsettings 
(Muhamed et al., 2020). ARF is caused by the response of the body’s autoimmunity to the 
infection of the throat due to Streptococcus pyogenes, also known as the group-A Streptococcus 
bacteria (Kumar and Tandon, 2013). ARF manifests as myocarditis, chorea, polyarthritis and 
erythema marginatum or a rash (Guilherme, Köhler and Kalil, 2011). The global burden of 
ARF and RHD is high, and is mainly observed in populations living in lowresource settings 
(Carapetis, 2007). In 2005, approximately 471,000 global AFR cases were reported and those 
were mostly children and teenagers between the ages of 5-15 years (Carapetis et al., 2005). 
Furthermore, the prevalence of RHD cases worldwide ranged between 15.6 and 19.6 million 
(Carapetis et al., 2005). An estimated 350,000 deaths occur each year due to ARF or RHD 
(Carapetis et al., 2005). Approximately, 34.2 million cases concomitant with 10.1 million 
disability-adjusted life years lost in 2010 were due to RHD and this contributed to the high 
global burden (De Dassel et al., 2015). There are several risk factors responsible for ARF and 
RHD which includes gender, age and multiple environmental factors (Carapetis et al., 2016). 
Although ARF statistics do not differ much between male and female, RHD is known to 
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commonly affect females (Lawrence et al., 2013). However, it is not fully elucidated whether 
the difference in RHD prevalence is caused by a higher susceptibility to autoimmune responses 
after S. pyogenes infection, or whether social factors (such as how the child was raised) 
increases susceptibility of S. pyogenes infection (Carapetis et al., 2016). Rural areas, remote 
areas as well as urban slums are associated with household crowding because of low 
socioeconomic status or limited access to medical resources (Carapetis et al., 2016). Therefore, 
one of the environmental factors that play a role is crowded households, which increases the 
likelihood of ARF and promotes the spread of S. pyogenes infections.   
  
1.1.2.2 Ischemic heart disease  
  
IHD also called coronary heart disease (CHD) comprises insufficient blood or oxygen 
circulation to the myocardium, and this is caused by thickening of coronary arteries causing 
them to narrow, these arteries usually supply blood to the myocardium (Gaze, 2013). Even 
though the narrowing of these coronary arteries can be due to vasoconstriction, most times it is 
caused by a build-up of plaque during called atherosclerosis (Soler and Ruiz, 2010). In the early 
stages of CHD, most people do not experience any symptoms (Soler and Ruiz, 2010). However, 
during the progression of atherosclerosis, especially if left untreated for a long period, 
symptoms are most likely to occur (Yelle, 2000). CHD is one of the key deaths causes in both 
men and women. From 2003 to 2006, approximately 17.6 million Americans aged 20 above 
had CHD, with an overall prevalence of 7.9 percent, and 9.1 percent of that men while 7 percent 
are women (Sani et al.,2006; National Centre for Health Statistics, 2016). CHD is accountable 
for more than half of all CV episodes in men and women under age 75 and above (Lloyd-Jones 
et al., 2010). Age and gender are known risk factors of CHD. In term of age, CHD largely 
affects people between the ages 40-75. While when it comes to gender, CHD commonly affects 
men. In addition, the lifetime risk of developing CHD after age 40 is 49 percent for men and 
32 percent for women (Lloyd-Jones et al., 2009). According to an estimate by Global Burden 
of Diseases Project the death rate of men due to IHD is higher compared to women with CHD 
and this had created a financial burden worldwide and account for about $177.1 billion of direct 
and indirect cost in 2010 (Lloyd-Jones et al., 2010). The World Health Organization (WHO) 
reported in 2005 that IHD was responsible for approximately 361 000 deaths in the African 
region and it has also been estimated that these projections will continue to increase almost as 
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1.1.2.3 Hypertensive heart disease  
  
HHD includes several complications associated with blood pressure. In HHD, the workload of 
the heart increases, consequently leading to enlargement of the myocardium. There are several 
factors documented that are believed to be responsible for the development of HHD and these 
factors continue to increase substantially (Diamond and Phillips, 2005). HHD is underpinned 
by increased myocardial fibrosis, apoptosis, endothelial dysfunction and inflammatory changes 
(Frohlich, 2009; Raman, 2010).   
  
HHD is characterised by left ventricular hypertrophy in response to increased high blood 
pressure (Drazner, 2011). HHD includes complicated abnormalities such as left ventricular 
hypertrophy, impaired diastolic and systolic pressure. Clinically, HHD as arrhythmias and 
symptomatic heart failure (Drazner, 2011).  Moreover, HHD is a result of the indirect and direct 
consequences of chronic high blood pressure (Tackling and Borhade, 2019), or the interplay 
between genetic and hemodynamic factors (Diamond and Phillips, 2005). Most of the factors 
responsible for HHD seem to involve the renin angiotensin aldosterone system (RAAS). 
However, recently discovered pathways also play a role, such as such as the human type-A 
natriuretic peptide receptor gene and G-coupled protein β 3-subunit gene (Diamond and 
Phillips, 2005). Most of the genetic factors responsible for HHD seem to target the renin 
angiotensin-aldosterone system (RAAS), these genes include the ACE and angiotensinogen 
genes. In a study conducted by (Brilla, Funck and Rupp, 2000), ACE inhibitors were used to 
treat myocardial fibrosis (which is one of the end-organ effects of HHD) and treatment 
minimised myocardium fibrosis by blocking the RAAS and thus, also reduce hypertension.   
  
1.1.3 Risk factors of CVDs: Key role of hypertension  
  
Most CVDs are preventable and therefore the increased awareness programs on behavioural 
risk factors such as the use of tobacco, obesity related to unhealthy diet, physical inactivity, 
and excessive use of alcohol are crucial (Maarman et al., 2020). These risk factors contribute 
to the development of diabetes, obesity, and hypertension (WHO, 2017).  Hypertension is a 
condition that comprises elevated blood pressure in the absence of medical treatment (WHO, 
2015). It can result in serious complications such as heart disease, stroke, and ultimately death 
(George et al., 2018). Hypertension remains the deadliest risk factor for CVD in low-income 
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countries (Ntuli et al., 2015), and the WHO reported that about 1.13 billion people worldwide 
have hypertension, mostly those living in low/middle-income countries (World Health 
Organization, 2011; Basu and Millett, 2013). Additionally, in Sub-Saharan Africa, the 
prevalence of hypertension ranges from 5%-50%, whereas in developed countries it ranges 
between 19%-30% (Woodiwiss et al., 2011). Hypertension in developed countries is a 
continuously growing health concern (Woodiwiss et al., 2011), and when comparing low, 
middle-income countries and high-income countries, hypertension is higher in low/middle-
income than in high-income countries, with 28.5% (which is 349 million people) cases of 
hypertension (Mills, Stefanescu and He, 2020).   
  
Data from the National Health and Nutrition Examination Survey (NHANES), spanning 
20112014, demonstrated that in age groups 20 and above, 86 million adults had hypertension, 
with a prevalence of 34% (Benjamin et al., 2017). Data from the Centres for Disease Control 
and Prevention's (CDC) National Centre for Health Statistics (NCHS), spanning 2015-2016, 
the hypertension prevalence was 29% among people aged 18 and older (National Centre for 
Health Statistics, 2017). In African Americans, the prevalence of hypertension is one of the 
highest compared to any ethnic group worldwide, at 45% for males and 46.3% for females 
(National Centre for Health Statistics, 2017). The prevalence rate for Caucasian men is said to 
be 34.5% with 32.3% for women, while Hispanic men account for 28.9% and 30.7% for women 
(Benjamin et al., 2017). Moreover, black Americans are reported to have high prevalence of 
hypertension, and are therefore, at higher risk of developing heart failure (Tackling and 
Borhade, 2019). Worldwide, roughly 26% of the world’s population, which is 972 million 
people, have hypertension (Mills, Stefanescu and He, 2020). This prevalence of hypertension 
is expected to increase to 29% by 2025, an increase that is attributed to the economic 
development of nations across the world (Mills, Stefanescu and He, 2020). The continuous 
increase in the prevalence of hypertension is a public health concern and financial burden 
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1.1.4 Contribution of RAAS to the pathogenesis of hypertension  
  
The RAAS is a major endocrine or paracrine system involved in the regulation of a myriad 
cardiovascular processes (Iravanian and Dudley., 2008). It is not only known for circulating 
hormones but plays a role in modulating numerous neurologic patterns in the brain 
(Labandeira-García et al., 2014). This complex system has important physiological functions 
including control of water and electrolytes, systemic vascular resistance, blood pressure and 
cardiovascular homeostasis. The RAAS also regulates hemodynamic stability by controlling 
blood pressure through the regulation of vasoconstriction, sodium reabsorption, body fluid 
homeostasis (Atlas & Steven, 2007). Therefore, any disturbance in the RAAS has been 
implicated in the pathogenesis of hypertension. For example, differences in genes encryption 
for renin (Kurtz et al., 1990), angiotensin-converting enzyme (Jacob et al., 1991; Hilbert et al., 
1991), angiotensinogen (Hata et al., 1994; Jeunemaitre et al., 1992) and angiotensin receptor 
(ATR) (Bonnardeaux et al., 1994) have been linked with hypertension in animal models and 
human populations of sodium-sensitive hypertension. Chronic stimulation of the RAAS can 
also lead to widespread oxidative stress, inflammation and endothelial dysfunction, which may 
consequently result in severe hypertension, kidney disorders and heart failure (Jackson et al., 
2018). The role of RAAS in the pathogenesis of hypertension (Cowan and Young, 2009), 
cardiac hypertrophy (Cowan and Young, 2009), and atherosclerosis has been confirmed 
previously. During the beginning stages of heart failure, the RAAS is stimulated as a 
compensatory mechanism to minimise to progression of cardiac pathology. However, as the 
disease progresses it assumes a harmful role which is responsible for an increase in cardiac 
preload and afterload, a hallmark of clinical heart failure syndrome (Iravanian and Dudley Jr., 
2008).  
  
The mechanism begins with activation of RAAS system in response to low BP, drop in 
intratubular sodium (Ren et al., 2019; Cowan and Young, 2009). The specialized cells called 
juxtaglomerular (JG) cells within the afferent arterioles of the kidney become activated, the 
activation of JG cells cause a release an inactivated form of renin enzyme. Once renin has been 
released in the circulation, it acts on its target, angiotensinogen, and catalyses the cleavage of 
angiotensinogen into Ang-I. Ang-I is normally inactive but acts as an Ang-II precursor. 
Thereafter, Ang-I is converted to Ang-II by an enzyme called angiotensin converting enzyme 
(ACE). ACE is situated primarily on the intimal side of the vascular endothelium in lungs and 
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kidneys. After conversion of Ang-I to Ang-II, Ang-II influences its target organs such as kidney, 
adrenal cortex, arterioles, and brain by attaching itself to Ang-II type-I (ATI) and type II (ATII) 
receptors.   
  
Ang-II is a hormone of the RAAS known to play a crucial role in the progression of 
hypertension and contributes to the pathogenesis of CVD (Pushpakumar et al., 2013). The 
physiological action of Ang-II is brought about by binding to specific extracellular receptors 
(Ito et al., 1995). Ang-II receptors belong to rhodopsin-like G-protein family associated 
receptors and have been divided into two pharmacologically distinct types designated type-1 
(AT1) and type-2 (AT2) (Chai et al., 2012). Ang-II is responsible for stimulating the secretion 
and synthesis of aldosterone through the AT1-R in the adrenal cortex. Aldosterone is, in turn, 
responsible for sodium reabsorption, water retention, and loss of either potassium or 
magnesium. Furthermore, aldosterone modulates volume of extracellular space and blood 
pressure through a specific mechanism on the nephron of the kidney (Crowley et al., 2006; 
Unger, 2002).  
  
Ang-II in the brain has three effects to exert control over systemic blood pressure. Firstly, Ang-
II attaches itself to the hypothalamus, activating thirst and thereby increasing water intake 
(Jackson et al., 2018). Secondly, it causes release of antidiuretic hormone (ADH) through the 
posterior pituitary. ADH stimulate an increased water reabsorption in the kidney by putting 
aquaporin channels at the collecting duct (Young and Davisson, 2015). Lastly, Ang-II causes 
a decrease in baroreceptor reflex sensitivity. This reduces the response of baroreceptor to an 
increase in blood pressure, which would be counterproductive to the goal of the RAAS. Ang-
II also acts on the proximal convoluted tubule of the kidney, it causes an increase in the Na-H 
exchange thereby increasing sodium reabsorption. Once the sodium is increased in the body it 
causes an increased osmolarity of blood, subsequently causing fluid to move into the blood 
volume and extracellular space. This in turn causes an increase in the arterial blood pressure 
(Wright and Harding, 2013; Jackson et al., 2018).  
  
Finally, Ang-II effects vasoconstriction in systemic arterioles. This begin by Ang-II binding to 
the G-protein-coupled receptors, causing a cascade of secondary messengers that lead to potent 
arteriolar vasoconstriction. This in turn causes an increase of total peripheral resistance, causing 
an increased blood pressure. On the other hand, though RAAS is responsible for such crucial 
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physiological processes, it can be inappropriately activated in many conditions that most likely 
promotes the development of hypertension. For example, in renal stenosis, which is the 
constriction of the arteries that carry blood to one or both kidneys, the juxtaglomerular cells 
become activated and detect a decrease in blood volume, and this activates the RAAS system. 
In turn, this can cause an inappropriate increase of circulating blood stream volume and 
arteriolar tone caused by poor renal perfusion (Ren et al., 2019; Santos et al., 2019).   
  
Collectively, recent findings have demonstrated that the primary action of Ang-II in the 
development of hypertension is mediated through AT1R (Mascolo et al., 2017; Jackson et al., 
2018). In addition, the primary actions of AT1R are pre-hypertensive. Pre-hypertension is when 
blood pressure levels are above normal or rather optimal level. WHO categorizes 
prehypertension as a blood pressure measurement between 120/80 and 139/89 (Chamarthi et al., 
2010). The important role of AT1A receptors in pre-hypertensive was verified by Ito and 
colleagues (Ito et al., 1995) in type-1A Ang-II receptor gene AgtrIA (-/-) mutant animals. 
Compared with AgtrIA (+/-) herezygotes systolic blood pressure was significantly reduced, and 
it was further reduced in AgtrIA-/-. They further suggested that AgtrIA receptor function is 
needed for the response of blood pressure and hemodynamic to Ang-II. Their study has proven 
significance of the AgtrIA gene in controlling blood pressure in mice (Ito et al., 1995). The above 
data are in accordance with previous studies indicating that AT1A receptors play an essential 
role in blood pressure control (Červenka et al., 2002). They found that targeted disturbance of 
the AT1A receptor gene eliminates the chances of development of 2K1C Gold blatt (two kidneys, 
one clip) hypertension model in mice, moreover, proposed that for the development of 2K1C 
hypertension, the presence of AT1A receptors is critical (Červenka et al., 2002).  
  
The study conducted by (Broekmans et al., 2015) looking at Ang-II induced hypertension in 
nitric oxide (NO)-sensitive guanylyl cyclase-1 knockout mice (NO-GC1 KO), agrees with the 
study conducted by Muthalif and colleagues who also observed increased blood pressure in rat 
arteries due to Ang-II treatment (Muthalif et al., 2000). Broekmans and his team treated male 
NO-sensitive guanylyl cyclase-1 NO-GC1 KO mice lacking the a-1 subunit of the 
heterodimeric NO-GC1 (a1b1) and wild type for two-weeks, at the end of the experiment they 
found that the treatment resulted in an increased systolic blood pressure, which was similar in 
wild type and NO-GC1 KO mice. Another study showed similar results with the two above 
studies with an exaggerated increase in blood pressure in rats that received a chronic infusion 
Stellenbosch University https://scholar.sun.ac.za
 
   13  
    
of Ang-II (Nahey and Collister, 2007). These results indicate that Ang-II induced increased 
blood pressure independent of NO-GC as reduced sympathetic activity in the NO-GC1 KO 
mouse model prevents hypertension. Therefore, it was speculated that there could be a 
possibility of sympatho-excitatory action of NO-GC1 counteracting NO-GC1’s dilatory effect 
in the vasculature (Broekmans et al., 2015).  
  
1.2 Impact of hypertension on the myocardium   
  
Hypertension induces coronary arteriolar constriction and inflammatory changes in the 
myocardium (Raman, 2010). An increase in blood pressure involves alteration in the 
myocardium, which over time affects the cardiac structure (Bernardo et al., 2010). This is 
manifested by cardiac growth and cardiac remodelling that may also occur as an outcome of 
pressure overload (such as systemic blood pressure) leading to pathological cardiac 
hypertrophy (Bernardo et al., 2010). This remodelling may occur with the onset of hypertension 
or as the progressive evolution of the structure of the infarcted scar. During early stages, the 
myocardium continues to function normally as it compensates for the elevated 
workload/pressure by becoming hypertrophied. The consequential structural and functional 
changes in the myocardium leads to left ventricular hypertrophy (Diamond and Phillips, 2005). 
The process of cardiac hypertrophy is complex and comprises several role players. In response 
to diverse stimuli of cardiac stress, cardiac fibroblasts become stimulated, at the end, to undergo 
physical conversion to myofibroblasts (Czubryt, 2019), followed by enlargement of the 
interstitium, a major increase in accumulation of collagen in between myocytes and fascicles 
(Eckhouse and Spinale, 2012) and a decrease in intramyocardial capillary density which gives 
rise to impairments in diastolic filling (Drozdz and Kawecka-Jaszcz, 2014). Extracellular stress 
mediated by pressure overload and stretch-activated ion channels are accountable for 
transmission-intracellular signals into the nucleus, to increase hypertrophic gene expression 
(Drozdz and Kawecka-jaszcz, 2014).   
  
During this myocardial remodelling, fibroblasts become the dominant cell type in the infarcted 
myocardium and undergo dramatic phenotypic changes to myofibroblasts (Pushpakumar et al., 
2013). Impairments associated with high blood pressure on the myocardium start small and 
build up over time if not detected early. It begins with blood vessels and major arteries that are 
responsible to carry blood throughout the body to the vital organs and tissues (Lifton RP, 
Gharavi AG, 2001). Thus, when the pressure exerted on the arterial wall in excessively increase, 
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as with hypertension, it causes disruption of the arterial wall (Nickerson et al., 1992). Over 
time, cholesterol deposits collect at the site of arterial damage, a plaque builds up and causes 
narrowing of the arterial lumen, reducing the blood flow that can lead to an acute myocardial 
infarction (Sathnur et al., 2013) (see Figure 2)  
  
 
Figure 2: Representation of a balance between blood pressure and hypertrophy. Increase 
in blood pressure lead to constriction of blood vessels, arterioles, decreased blood flow to the 
rest to the body and reduced contractility and subsequently formation of abnormal diastolic 
function and heart failure.  At the same time the heart tries to compensate from increased blood 
pressure by enlarging the left ventricle to minimize wall stress in a process called cardiac 
hypertrophy.   
  
The chronic pressure overload that hypertension exerts on the myocardium predisposes to 
abnormal cardiac contraction and dilation of the ventricular wall (Petriz and Franco, 2014). 
Eventually, because the elevated blood pressure persists, the left ventricle compliance and 
diastolic filling pressure declines, leading to heart failure. Approximately 60% of left 
ventricular mass variance is most likely to be due to genetic factors independent of blood 
pressure (Diamond and Phillips, 2005). Hypertension activates mechano-sensing mechanisms 
in cardiomyoblasts via myocardial stretch that releases ion channels, growth factor receptors, 
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regulation and protein synthesis (Bernardo et al., 2010; Rosca et al., 2013) to induce 
intracellular transfer of signals to the nucleus, in order to increase hypertrophic markers 
(Drozdz and Kawecka-jaszcz, 2014).   
  
The renin-angiotensin-aldosterone system (RAAS) is one of the key hormonal mechanisms that 
controls hemodynamic stability through regulation of blood pressure, fluid volume, and sodium-
potassium balance. Thus, any destruction in one of the molecules that compose RAAS promote 
developing of hypertension (Te Riet et al., 2015). One of the RAAS molecules is AngII which 
is the main vasoactive molecule known for inducing development of hypertension. Ang-II is 
known for its modulating function in contractile-related molecular expression (skeletal 𝛼𝛼-actin, 
𝛽𝛽-myosin heavy chain, atrial natriuretic polypeptide, and fibronectin) and promote cardiac 
phenotype remodelling (Kim et al., 1995) and hypertrophy. Initiation of biochemical events such 
as the translocation of NFAT, causes the modification of cardiac gene transcription in the nucleus 
(Crowley et al., 2006). Apoptosis is an additional consequence of hypertension (González et al., 
2003). Hypertension is therefore responsible for many impairments in the heart, especially in 
relation to cardiac hypertrophy (Petriz and Franco, 2014). Left ventricular hypertrophy is a well-
recognized characteristic of compensatory mechanism to try and adapt to increased pressure and 
an essential criterion of hypertensive heart disease (Frohlich, 1999).   
  
1.2.1 Signalling pathways of hypertrophy  
  
The regulation of cardiac hypertrophy can be categorised into two major pathways either as 
physiological or pathological (John et al., 1999). Physiological hypertrophy is associated with 
athletes and is linked to corresponding incremental increase in length and width in 
cardiomyoblasts (John et al., 1999), while pathological hypertrophy is linked to an increase in 
fetal gene expression, fibrosis, and cardiac dysfunction (McMullen and Jennings, 2007). Both 
of these types of hypertrophy are initiated in response to different stimuli, a difference in 
structure, molecular phenotype and each function different from one another (McMullen and 
Jennings, 2007). In pathological hypertrophy, the increased size in cardiac myocytes and how 
new sarcomeres are formed primarily serves to minimize wall stress and allow cardiovascular 
system to function normal at rest (i.e. Compensated growth). On the other hand, the way in 
which hypertrophied heart function may eventually decompensate, causing a left ventricle 
dilation and heart failure (Hort, 1985). While, physiological hypertrophy does not 
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decompensate into dilated cardiomyopathy or HF (Pluim et al., 2000). Physiological and 
pathologic hypertrophy can further be subdivided into either concentric or eccentric, with 
regards to transformation of cardiomyoblasts in shape depending on the initiating stimulus 
(Pluim et al., 2000; McMullen and Jennings, 2007). For example, a pathological stimulus such 
as hypertension results in chronic pressure overload that leads to concentric hypertrophy (Pluim 
et al., 2000; McMullen and Jennings, 2007). On the other hand, the stimulus responsible for 
volume overload results in an increased diastolic wall dimension (Grossman et al., 1975). Also, 
pathologic cardiac hypertrophy development can also result from oxidative stress resulted from 
either led by either pressure or volume overload (Diwan and Dorn, 2007).   
 
Figure 3: Schematic diagram of Ang-II on cardiomyocyte hypertrophy. Ang-II stimulation 
caused an increase in intracellular calcium which activates calcium-calmodulin-activated 
protein phosphatase Calcineurin. Increase in calcium in turn activates PKC which increases 
activation of GSK-3β, thereby, inhibit hypertrophy. Calcineurin/NFAT pathway is also 
responsible for hypertrophy but is blocked by GSK-3β (including the decrease in hypertrophy 
markers such as mRNA level of BNP, ANF, and cell surface area). This diagram was adapted 
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Cardiac hypertrophy is regulated by various stimuli, and these stimuli (Hunter and Chien, 1999) 
activates membrane receptors and intracellular signalling pathways to mediate the transcription 
of hypertrophy-related genes (Van Berlo et al., 2013). These genes include c-fos, myc, as well 
as foetal genes which include atrial natriuretic factor (ANF), β-myosin heavy chain (βMHC), 
and skeletal alpha-actin (SKA) (Figure 3) (Van Berlo et al., 2013). When the cardiac 
hypertrophic status is prolonged subsequent pathological cardiomyocyte growth occur, 
identified by an alteration in the extracellular matrix as well as abnormal adrenergic response, 
and alteration in the expression of proteins (Diwan and Dorn, 2007; Bernardo et al., 2010).  
  
Cardiomyoblasts have little or no ability to proliferate, and therefore, their only method of 
growth is hypertrophy (Diwan and Dorn, 2007). Generally, left ventricular hypertrophy is 
characterized by increased cardiomyocyte size, underpinned by elevated protein production 
and transformation in structures of the sarcomere (Carreño et al., 2006). Many factors can 
induce left ventricular hypertrophy and these include endothelin-1 (ET-1), catecholamine, 
growth factors and Ang-II (Zhang et al., 2004). Among these, Ang-II has commonly been used 
to induce left ventricular hypertrophy in experimental models, with concomitant pressure 
overload which leads to concentric hypertrophy (Marketou et al., 2016). Other pathways 
involved in this effect of Ang-II includes activation of G-coupled protein receptors, the 
calcineurin-nuclear factor of NFAT signalling pathway, the mitogen‐activated protein kinase 
(MAPK) signalling pathway and PI3K/Akt/GSK‐3β signalling pathway (Figure 3) (Heineke & 
Molkentin, 2006).  
  
Membrane bound ATR1, Ang-II binds to their ligands resulting in receptor colocalization that 
induces a significant increase in accumulation of inositol-3 phosphate which signals the 
sarcoplasmic/endoplasmic reticulum to release calcium into the cytosol (Unger, 2002) (Figure 
3). The increase in cytosolic calcium activates calcium-calmodulin-activated protein 
phosphatase Calcineurin. Once activated, calcineurin directly dephosphorylates members of 
NFAT transcription family in the cytoplasm, promoting their translocation to the nucleus. Once 
the NFAT family members are in the nucleus, they contribute to the transcriptional induction 
of different immune response genes in T-cells, and genes with diverse functions in other cell 
types (Hogan et al., 2003; Gomes et al., 2012). The NFAT in the nucleus can be phosphorylated 
by GSK-3ß thereby promoting its nuclear export (McKinsey and Olson, 2005). Calcineurin 
activity is negatively regulated by overexpression of GSK-3ß, which directly affects the N-
Stellenbosch University https://scholar.sun.ac.za
 
   18  
    
terminal regulatory domain of NFAT by phosphorylating it, thus counteracting the action of 
Calcineurin and blocking nuclear shuttling of NFAT (Carreño et al., 2006). Once GSK-3ß is 
overexpressed in cultured cardiomyoblasts it inhibits agonist-induced hypertrophy, by 
preventing NFAT from translocating to the nucleus (Antos et al., 2002). (Carreño et al., 2006) 
(Figure 3).   
  
Ca2+/Calcineurin–NFAT signalling is one of the major pathways responsible for the 
development of cardiac hypertrophy (Guan et al., 2017). The Calcineurin–NFAT signalling 
pathway may also work with other pathways inducing hypertrophy, these pathways include 
MAPK/ERK, PI3K/AKT, P38 and JNK (Molkentin, 2004). MAPK/ERK and PKB/Akt 
pathways can be sensitive when it comes to reactive oxygen species (ROS) and they play a 
major part in the development of hypertrophy using a variety of stimuli such as 
volume/pressure overload, mechanical stretch and GPCR (Heineke & Molkentin, 2006). 
Accumulating evidence supports a physiological role for ROS as a “second messenger” in 
intracellular signalling cascades that control cell growth and proliferation (Hoidal, 2001). 
PKB/Akt pathway also induce hypertrophy via increase in expression mTOR (Shioi et al., 2002) 
and the inactivation of GSK-3β (Haq et al., 2000). However, as compared to other kinases, 
GSK-3β is highly active in unstimulated cells and becomes inactivated in response to mitogenic 
stimulation (Starksen et al., 1986). The activity of GSK-3β is regulated by phosphorylating the 
serine-9 site. The increase in phosphorylation of this site inhibits the activation of GSK-3β by 
creating an inhibitory pseudo-substrate for the enzyme (Dajani et al., 2001). In contrast, once 
the serine-9 site is dephosphorylated it subsequently blocks phosphorylation of GSK-3β, 
leading to the activation of the kinase cascade. Several protein kinases, including Akt protein 
kinase B (PKB), have been shown to phosphorylate serine-9 of GSK-3β in response to 
mitogenic signalling, consequently inactivating the enzyme (Cross et al., 1995). The ability of 
GSK-3β to inactivate NFAT proteins by preventing their accumulation in the nucleus suggests 
that GSK-3β might possess anti-hypertrophic activity (Antos et al., 2002).  
  
Excessive increases in pressure stimulates neurohumoral mediators that trigger the activation 
of membrane bound receptors such as tyrosine kinases, cytokine receptors and GPCRs (Scott, 
2004). Stimulation of GPCR-like adrenergic receptors can trigger activation of G-proteins, 
which in turn can lead to production of cAMP. The latter can lead to stimulation of Ca2+ 
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regulatory proteins and myofilament proteins. Moreover, this causes a transformation in 
sarcomeric protein production and hypertrophy (Perez et al., 2003; Small et al., 2002).  
  
1.2.1.1 The role of mitochondria in cardiac hypertrophy  
  
Mitochondria were the first subcellular organelles to be dissected. Mitochondria are made up of 
two bilayer membranes that create two recognizable compartments: an intermembrane space and 
a matrix space within the inner membrane. The outer mitochondrial membrane consists of 
proteins known as porins. Porins enable in and out movements of the ions from the 
mitochondrion. while the inner mitochondrial membrane contains different types of enzymes 
(El-Hattab and Scaglia, 2016). The inner part of the mitochondria consists of the energy 
generating multiple polypeptide enzyme complexes called the electron transfer system (ETS). 
(El-Hattab and Scaglia, 2016). Mitochondria are present in human cells containing a nucleus, 
and each cell type has several mitochondria based on their energy needs. Mitochondria are 
important sources of energy and they achieve this energy production through oxidative 
phosphorylation (Lu et al., 2013). The heart has a high energy demand because it must contract 
from birth to death, and therefore the heart contains millions of mitochondria. There are several 
proteins accountable for keeping mitochondrial structure and function intact so that they can 
produce ATP optimally. However, few are coded from mitochondrial DNA (mtDNA), while 
about 99% or more of other proteins are coded from nuclear DNA (nDNA). This suggests that 
mitochondria are is regulated by two types of proteins, mitochondrial and nuclear (El-Hattab and 
Scaglia, 2016).   
  
Ang-II, endothelin-1, platelet-derived growth factor (PDGF), and tumour necrosis factor 
(TNF)-α trigger production of mitochondrial ROS in the left ventricle via the NADPH oxidase, 
which results in cardiomyocyte apoptosis and hypertrophy (Mattera et al., 2017). Ang-II 
induces cardiac hypertrophy and apoptosis by increasing a ROS dependent molecular 
signalling pathway (Figure 4). In addition, mitochondria act as a major regulator of cell death 
and hypertrophy. Therefore, Ang-II stimulates mitochondrial dysfunction, subsequently 
produce an excessive amount of ROS (Dao-Fu Dai et al., 2013). This ROS increases the outer 
mitochondrial membrane permeability, leads to a release of pro-apoptotic protein cytochromec 
into the cytosol. Furthermore, activating caspase proteases, this ultimately led to apoptosis 
(figure 5) (Susin & Zamzami, 1996). Also, the release of mitochondrial ROS can lead to the 
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activation kinase cascades responsible for hypertrophy development such as PKB/Akt, GSK3ß, 
MAPK (Rosca et al., 2013; Kindo et al., 2012; Abel and Doenst, 2011).  
  
 
Figure 4: Ang-II induced hypertrophy and apoptosis converge into the mitochondria. 
Ang-II induce both hypertrophy and apoptosis. This bioactive octapeptide in the RAAS, 
mediates its effect via AT1R. Ang-II-ATIR stimulates both growth and apoptosis by activating 
reactive oxygen (ROS) dependent molecular signalling pathways that involve the mitochondria 
and NADPH oxidase (NOX). There is a crosstalk between hypertrophy and apoptosis and it is 
mediated by Mitochondrial ROS-dependent pathways. This figure was adapted from (Dai et 
al., 2011).  
  
ROS acts as intracellular signalling molecules that control cardiac hypertrophy and are well 
recognized for their destructive effect, which vary with the concentration or macromolecular 
damage. Thus, ROS acts as one of the crucial contributors to the activation of apoptotic 
pathway of the cell (Azizi et al., 2011). Cardiomyoblasts are known for undergoing apoptosis 
as a secondary mechanism to oxidative stress which in turn, promote a development CVD (Liu 
et al., 2011). In addition, the overproduction of mitochondrial ROS is known to cause an 
increase in oxidation of membrane lipid and an increase in intracellular calcium. Accumulation 
of calcium in the heart can lead to increase mitochondrial membrane permeability, which in 




   21  
    
  
Mitochondria are central to the regulation of cardiac apoptosis and hypertrophy, as they become 
abnormally stimulated to produce excessive concentrations of ROS (Liu et al., 2004).  
Furthermore, the balance between cardiac apoptotic and hypertrophic signalling is essential for 
the determination of the cell fate, and mitochondria are the biological sites where the cell’s fate 
will be determined (Pang et al., 2004; Fortuño et al., 2001). On the other hand, Ang-II also 
activates a redox-sensitive pathway during the development of cardiac hypertrophy and 
cardiomyocyte apoptosis (Siasos et al., 2018). The mechanism through which NADPH oxidase 
(NOX) triggers these two pathways involves ROS-mediated activation of multiple kinase 
cascades that are responsible for both hypertrophy and apoptosis (figure 4) (Siasos et al., 2018). 
Thus, an increase in NOX activity is known to be parallel to MAPK activation such as ERK 
1/2 and P38. Once NOX activity is increased, MAPK is also activated simultaneously. Ang-II 
also binds to G-protein coupled receptors and activates cytoplasmic signalling such as 
increased release of intracellular calcium, which in turn either activates calcium-calmodulin 
calcineurin or alters mitochondrial membrane gradient increasing membrane permeability 
(Figure 4). Subsequently cardiac hypertrophy is caused by cellular apoptosis followed by 
changes in the organization of myofilaments, depolarization of mitochondrial membrane 
potential, alteration of Bcl-2 genes, DNA mutation, active caspase cascade, release of 
cytochrome-c and nuclear chromatin condensation (Adams et al., 2000). Furthermore, evidence 
suggest that mitochondria are the major activators of caspase cascades in mammalian cells 
(Figure 4) (Green et al., 1998). Depolarization of mitochondrial membrane concomitant with 
cytochrome-c release and other apoptotic proteins such as Smad into the cytoplasm, which in 
turn lead to activation of caspases and ultimately lead to apoptosis (Adams et al., 2000).  
  
In addition, under stressful conditions, mitochondria become the main source of ROS 
production, generated mainly in the ETS via electron leakage (Ide et al., 2001). Superoxide is 
accountable for enlargement and death in cardiomyoblasts (Liu et al., 2005; Tsutsui & 
Kinugawa, 2009). ROS production can also occur via superoxide (O2-) producing enzymes and 
xanthine oxidase. Even though NADPH oxidase is the major site for synthesis of O2- the role 
they play to overall elevation in ROS is not well elucidated (Ago et al., 2010). Thus, 
mitochondria are assumed to be implicated in the pathology of multiple cardiovascular diseases, 
concerning the basic functions of the organelle, which therefore means they are central to both 
hypertrophy and apoptosis pathways (Dominic et al., 2014). Mitochondria are therefore 
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regarded as central to all metabolic processes including oxidative phosphorylation, beta 
oxidation, steroid and heme biosynthesis, intermediary metabolism, programmed cell death and 
innate immunity (Suárez-rivero et al., 2017). Various types of CVD are associated with 
mitochondrial damage such as inflammation, lysis of the mitochondria among those is 
cardiomyopathy (Dominic et al., 2014; Trentadue et al., 2012) and hypertrophy (Siasos et al., 
2018; (Adams et al., 2000).   
  
In a study conducted in an in vitro model it shown that mitochondria were central to cardiac 
apoptosis induced by Ang-II, endothelin-1, or pressure overload (Newmeyer & Farschon, 1994) 
and that adenine nucleotide translocator (ANT) is also likely to play a part in the process 
(Halestrap & Brenner, 2003). ANT, the mitochondrial proteins, exchanges cytosolic ADP for 
mitochondrial ATP and communicates with outer mitochondrial membrane proteins and 
proteins of the matrix to trigger the mitochondrial permeability transition pore (mPTP) (Ruck 
et al., 1998; Halestrap & Brenner, 2003). Once the mPTP is open, it leads to depolarization of 
mitochondrial membrane potential, causing swelling of the matrix and outer membrane. This 
triggers a release of apoptotic proteins such as cytochrome-c, apoptosis-inducing factor, and 
pro-caspase (Susin et al., 1999). In addition, ANT is also known as a regulator of apoptosis 
(Hang et al., 2006).  
  
Decreased articulation of cardiolipin, an important phospholipid responsible for making sure 
mitochondria function is intact, instigates cytochrome-c release into the cytosol leading to 
apoptosis (Paradies et al., 2014; Iverson and Orrenius, 2004). A decrease in cardiolipin is 
associated with a loss in mitochondrial carrier activity, cytochrome levels including 
cytochrome-c. Therefore, it is important for cardiolipin to remain constant because of its 
important function in keeping the mitochondrial function maintained. This suggests that 
changes in cardiolipin directly influence cytochrome-c release from the inner mitochondrial 
membrane into the cytosol. In another study conducted in a hypertensive rodent’s model, it was 
uncovered that Ang-II diminished the elements of complex-III, ATP production, creatine 
kinase and triggers an increased cytochrome-c release and activation of caspase-3 from the 
non-functional organelles (Atlas and Steven, 2007; Liu et al., 2009). Overall, these studies 
illustrate that cardiac apoptosis and hypertrophy converge on the mitochondrion. This shows 
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The ATP synthesized in the mitochondria is dependent on the ETS that comprises four 
complexes (I-IV) plus many molecules of coenzyme-Q. Stepwise electron transfer results in 
the active pumping of hydrogen ions through complexes I, II out of the mitochondrial matrix 
into the intramembranous space (Stanley et al., 2005). Complex III is where oxygen 
consumption actively takes place while complex IV and V partake in the final step of the ETS, 
which is oxidative phosphorylation. In addition, the expression and function of major proteins 
linked to the OXPHOS, such as ETC complexes I-V and other molecules are important in 
controlling what is going on with mitochondrial energy synthesis via posttranslational 
modification (Stoll et al., 2016). Moreover, alteration of these proteins adjusts the performance 
of the complexes and thus transforms the efficiency of mitochondria to come into physiological 
heart function. Mitochondria are involved in several processes and pathways such as metabolic 
and cellular signalling pathways cell survival and apoptosis. (Scheffler, 2002).   
  
1.2.1.2 Signalling in the mitochondrion  
  
Mitochondrial functions are achieved through the activation of intricate signalling pathways 
(Chandel, 2014). Several studies have reported mitochondria as signalling organelles and the 
mechanisms through which they perform this function is either through the release of proteins 
such as in regulation of cell death via the release of pro-apoptotic molecules such as 
cytochrome-c when the cell is damaged (Liu et al., 1996; Tait and Green, 2010), mitochondria 
evolved as the main site of production of ROS, major signalling molecules in the cell (Chandel 
et al., 1998; Schieber and Chandel, 2014).   
  
Mitochondrial metabolites, which are normally regarded as intermediates of cardiac energy 
metabolism, can regulate post-translational modifications o proteins, or via affecting chromatin 
structure and function (Harada et al., 1999; Sciacovelli and Frezza, 2016), or by serving as a 
scaffold to configure signalling complexes (Biswas et al., 1999). Furthermore, mitochondria 
are key players in cardiac calcium signalling (Rizzuto et al., 2012). Mitochondria communicate 
with the rest of the cell via two signal transduction systems, namely retrograde and anterograde 
signalling (Rizzuto et al., 1993). Retrograde signalling is a signal transduction from 
mitochondria to the cytosol while anterograde signalling is a signal transduction from cytosol 
to the mitochondria. Anterograde signalling was mostly recognized through cytosolic calcium 
entering into mitochondria to regulate bioenergetics (Rizzuto et al., 1993). Mitochondria can 
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use their ROS to communicate with the rest of the cell under physiological conditions (Chandel, 
2014). Under physiological conditions, retrograde signalling is observed in hypoxic conditions 
that stimulate mitochondrial ROS release, subsequently leading to the stabilization of hypoxia 
inducible factor (HIFs) and genes that are responsible for metabolic adaption to low oxygen 
are also induced (Chandel et al., 1998). Based on an emerging model of mitochondrial specific 
ROS (mROS) and signalling, low levels of mROS are required to maintain homeostatic 
biological processes including oxygen sensing, epigenetics, autophagy, innate and adaptive 
immune responses, stem cell proliferation and differentiation, and hormone signalling (West et 
al., 2011; Hamanaka and Chandel, 2009), while once the mROS slightly increase it initiate 
pathways for adaptations to stress. Furthermore, low levels of ROS can also increase 
antioxidant production to counteract oxidative stress, while much higher increases in levels of 
mROS stimulate cell death or senescence (West et al., 2011; Hamanaka and Chandel, 2009). It 
is important to keep in mind that targets of mROS that relay signalling could be located whether 
in the mitochondrial matrix, the intermembrane space, or the cytosol (Chandel, 2014).   
  
Mitochondria also use their outer membrane as a platform for signalling complexes. For 
example, A-kinase-anchoring proteins (AKAPs), located on the outer membrane, enabling 
phosphorylation of cAMP-dependent kinases (PKA). These AKAPs bind to the camp 
dependent serine/threonine kinase, which gather PKA with various signalling proteins in a 
scaffold to produce a signalling hub, which can be used as a target for multiple subcellular 
localization to enable specific target of PKA-dependent signalling (Taylor et al., 2013). When 
the mitochondria are impaired, they can use several mechanisms to communicate with the rest 
of the cell, these include the release of metabolites, activation of AMPK, and changes in 
mitochondrial dynamics (Chandel, 2014). Firstly, the availability of metabolites has become 
an important mechanism to regulate signal transduction, in particular the acetylation and 
methylation and histone regulating epigenetic processes (Kaelin and McKnight, 2013). 
Moreover, mitochondria are responsible for generating acetyl-CoA and S-adenosyl-methionine 
(SAM) required for protein acetylation and methylation, respectively. Therefore, whatever 
changes or impairment in mitochondrial biology can have dangerous effects on the epigenetic 
state (Wellen et al., 2009; Shyh-Chang et al., 2013).  
  
During the cardiac ischemic state mitochondria are unable to produce ATP and this can regulate 
signalling by increasing of AMP levels and adenosine as the breakdown product (Colgan and 
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Eltzschig, 2012). Increase in AMP levels are associated with a decline in ATP content leads to 
activation of kinase AMPK.  In turn, AMPK abolishes various anabolic processes in the cell, 
promoting catabolic processes such as autophagy to ensure enough metabolic supply (Hardie 
et al., 2012). Adenosine, once is released into the cell, it participates in the stimulation of 
Gprotein-coupled receptors. As a result, metabolites and adenine nucleotides mostly thought 
to be implicated in biosynthetic and bioenergetic processes are also actively implicated in 
signalling (Colgan and Eltzschig, 2012).  
The ability of mitochondria to properly move around in the cell is necessary to ensure a proper 
dissemination of their signals to the correct targets (Campello and Scorrano, 2010). For 
example, during hypoxia mitochondria become clamped into the perinuclear region, enabling 
ROS release into the nucleus for hypoxic gene expression (Al-Mehdi et al., 2012). Normally, 
mitochondria in healthy cells are elongated and packed together into a ‘spaghetti-like” 
filamentous network. The rate of fusion and fission of mitochondria is properly controlled 
(Chan, 2012). However, when fission is out of control and becomes excessive it causes a 
destruction in the filaments network, thus, a punctate pattern and ultimately mitochondrial 
dysfunction. Furthermore, when fusion is also disrupted in the embryonic heart and stem cells 
in a mouse can lead to the disruption of development of the heart and also hinder differentiation 
of embryonic stem cells into cardiomyoblasts caused by an increase in Ca2+-dependent 
calcineurin activity (Kasahara et al., 2013). Homeostasis and signalling of calcium is crucial 
for a cell to function normally. It plays an important role in the beginning of life after oocyte 
fertilization, cell differentiation during development, intracellular and intercellular signalling, 
and ultimately for initiation of cell death (Berridge et al., 1998). Mitochondria are known to 
contribute a critical role in signalling and homeostasis of calcium.   
  
Mitochondria are divided into two groups depending no their primary function such as those 
found in excitable cells and those in non-excitable cells (Carafoli, 2012). In excitable cells, 
mitochondria can impact intracellular calcium in multiple ways. These cells include brain 
dendritic cells, cardiomyoblasts, and smooth muscle cells. Once the concentration of calcium 
increases, they store it in the mitochondrial matrix in the form of the main building block of 
bone called hydroxyapatite and tri-calcium phosphate. Therefore, mitochondria can propagate 
calcium-driven signals in two ways: one functioning as a calcium sink to block feedback 
inhibition, on the other hand, they function as a calcium source releasing a lot of calcium into 
the cytosol to intensify signals (Whelan and Zuckerbraun, 2013). Extended periods of 
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intracellular calcium increase are linked to an initiation of either necrotic cell death or 
activation of the apoptotic machinery (Bayir and Kagan, 2008).  
 
1.2.2 Apoptosis  
1.2.2.1 Signalling pathways of Apoptosis  
Apoptosis is another consequence of hypertension and is defined as programmed cell death 
(D’Arcy, 2019). It is characterised by shrinking of the cell, followed by DNA fragmentation, 
chromatin condensation, blabbing of the membrane and finally formation of apoptotic bodies 
(Lemasters, 2018). It can be initiated by either extracellular or intracellular stimuli resulting in 
the activation of caspase cascade and consequently cell death. The regulation of apoptosis can 
be initiated through one of three pathways (1) the death receptor pathway, (2) the mitochondrial 
pathway and (3) the granzyme A or B pathway (Bennett, 2002; Gustafsson and Gottlieb, 2003). 
Apoptosis can be further regulated by two simple pathways, the intrinsic/mitochondrial 
pathway and extrinsic/ death receptor pathway (Bennett, 2002; Gustafsson and Gottlieb, 2003). 
In the intrinsic or mitochondrial pathway, the cell basically commits suicide because it senses 
stress, while in the extrinsic pathway, which is via death receptors the cell, the cell is given 
instruction to commit suicide via signal transduction activators from other cells (Bennett, 2002; 
Gustafsson and Gottlieb, 2003). The last pathway which includes perforin/granzyme is 
mediated by cytotoxic T cells. In this pathway, the induction of apoptosis occurs through 
granzyme B or granzyme A (Bennett, 2002; Gustafsson and Gottlieb, 2003). All three pathways, 
except granzyme A have one thing in common, they all induce apoptosis through the execution 
pathway that ends with the activation of caspase-3 (Bennett, 2002; Gustafsson and Gottlieb, 
2003).  
  
1.2.2.2 The death receptor pathway  
  
Firstly, membrane bound death receptors which also form part of tumour necrosis receptor such 
as Fas or death receptors DR 3-6, bind to their trimerized ligand resulting in the receptors 
coming together and forming a homotrimeric complex, to recruit adapter proteins such as 
FasFADD, TNF-RI-TRADD via protein-protein communications (Wajant, 2003; Gustafsson 
and Gottlieb, 2003). In turn, these adapter proteins lead to the recruitment of caspase cascade 
such as caspase-8 (Boldin et al., 1996; (Portt et al., 2011) and caspase-2 to the homotrimeric 
complex (Penninger and Kroemer, 2003). Subsequent activation of caspase-8 and 2 lead to the 
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activation of downstream effector caspases, which include caspase-3, 6 and 7, responsible for 
the cleavage of intracellular substrates. These caspases are needed for culminating in cell death 
(Bennett et al., 1995), and for cellular survival, and metabolic function (Bennett, 2002) (figure 
5).   
  
 
Figure 5: Signalling pathways of apoptosis. Each pathway has a specific triggering signal to 
initiate its energy-dependent cascade of molecular events. Each pathway activates different 
initiator caspases such as 8, 9, and 10 and subsequently will activate the executioner caspase3. 
However, granzyme A works in a caspase-independent fashion. The activation of caspase-3 
(also called execution pathway) leads to several cytomorphological changes including cell 
shrinkage, chromatin condensation, formation of cytoplasmic blebs and apoptotic bodies and 
finally phagocytosis of the apoptotic bodies by adjacent parenchymal cells, neoplastic cells or 
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1.2.2.3 The mitochondrial pathway  
  
This pathway is also called the intrinsic pathway, during which mitochondria integrate different 
cellular stress signals such as growth factors, calcium or hypoxia (Gustafsson and Gottlieb, 
2003). In response to these signals, directly after activation of caspase, the activation of caspase 
8 leads to the cleavage of Bcl-2 and Bid. A family of Bcl-2 members can either be pro-apoptotic 
including Bax, Bid, Bik or anti-apoptotic such as Bcl-2 and Bcl-x (Saelens et al., 2004). Once 
the pro-apoptotic Bcl-2 family is activated, they move to the mitochondria where they 
communicate with anti-apoptotic members that are mitochondrial membrane components 
(Salakou et al., 2007). The interconnection between pro-apoptotic and anti-apoptotic members 
cause the depolarization of a voltage dependent mitochondrial channel, an increase in the 
mitochondrial permeability and thus the release of mitochondrial pro-apoptotic factors, 
cytochrome-c and apoptosis-inducing factor into the cytosol (Penninger and Kroemer, 2003). 
After cytochrome c has been released into the cytosol, it is associated with adapter molecule 
apaf-1 and caspase-9 to form a macromolecular complex called the apoptosome. Activation of 
this complex triggers the activation of caspase 3 and apoptosis (Zou et al., 1999; Jiang and 
Wang, 2000).  
  
1.2.2.4 Physiological roles of apoptosis  
  
Apoptosis also plays a physiological role in cell turnover, organ development, immunity and 
the nervous system (Empel et al., 2004) It is responsible for the maintenance of homeostasis in 
living organisms by depleting cells as a response to variety of stimuli. After the cells have been 
depleted by apoptosis, the tissue undergoes remodelling through cell proliferation (Porrello et 
al., 2008). The degree to which the remodelling is achieved, depends on the natural balance 
between proliferation and apoptosis (Porrello et al., 2008). Apoptosis is, therefore, a necessary 
mechanism controlling the overall yield of cell proliferation, ensuring that homeostasis takes 
place in all tissues in a well-regulated manner to avoid adverse cellular consequences 
(Sinkovics, 1998). It regulates cell homeostasis by maintaining an equilibrium between cell 
proliferation and cell death, and performs other functions like global cardiac structure, removal 
of several vestigial structures, the timely renewal of cells (Gustafsson and Gottlieb, 2003; 
(Elmore, 2007)). This equilibrium is aimed to maintain the balance between new cells being 
formed as old cells die. Programmed cell death allows this balance through the phagocytosis 
stage which allows the cell contents to be reused whilst providing a competent mechanism to 
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extract loads of cells, essential for the equality of cell life and death (Ulukaya et al., 2011; 
Mcwilliam, 2014).   
  
The amount of cell death by apoptosis that takes place during the development years of a human 
being, and adulthood is astounding. A practical example of apoptosis is when fingers and toes 
in a developing human embryo separate, the cells between the digits go through apoptosis. 
Apoptosis does not only occur during development and aging stages but also functions as a 
defence mechanism when cells are attacked by a disease or by dangerous agents (Norbury, 
2001). In addition, in adults, apoptosis is mainly significant in counteracting unrestricted 
proliferation and cyclic involution of several endocrine-dependent tissues. Apoptosis can also 
occur during the development of the nervous system, normally almost half or more of the nerve 
cells immediately die after their formation (Van Empel and De Windt, 2004). Moreover, 
apoptosis is considered a major role player in the development of the cardiovascular system, 
and it takes place at crucial time points during major developmental processes (Elmore, 2007). 
Apoptosis in the development of the nervous system occurs to minimize the number of nerve 
cells so they can match the targeted cell number that need innervation (Van Empel and De 
Windt, 2004).   
  
Apoptosis also plays an important role in the regulation of the immune system. It does this 
through T-lymphocytes, which are responsible for getting rid of infected or damaged cells in 
the body (Sinkovics, 1998). The T-lymphocyte cells grow and mature in the thymus. However, 
before they can go through circulation, they must be inspected to make sure they are effective 
against foreign antigens and also to ensure that they will not react against healthy cells. 
Therefore, any self-reactive or ineffective T-lymphocytes are removed through apoptosis 
(Adams et al., 2000). Lastly, apoptosis is involved in pregnancy, especially in the trophoblast 
cells which are responsible for the formation of the outer layer of a blastocyst. They invade the 
uterine environment to ensure maternal blood vessels are remodelled and also help to maintain 
a successful pregnancy (Sinkovics, 1998). Thus, apoptosis is needed to strictly control 
proliferation of cells. However, deregulation of apoptosis is commonly known and linked to 
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1.2.2.5 Pathophysiological roles of apoptosis  
  
Apoptosis plays a major role in the injury of the heart in IHD and HHD (De Meyer and Martinet, 
2009). IDH, reperfusion of the myocardium inhibits apoptosis induced by ischemia, during 
coronary artery ligation and acute myocardial infarction in an in vivo model (De Meyer and 
Martinet, 2009). However, even though reperfusion can reduce apoptosis induced by ischemia, 
on its own, it can also elevate apoptosis in the re-perfused parts (Bennett, 2002). For this reason, 
inhibiting apoptosis in the heart, has become a therapeutic target during myocardial 
ischemia/reperfusion injury (Bennett, 2002).   
  
Results from different in vitro, animal and human studies demonstrate that apoptosis of 
cardiomyoblasts plays an important part in the remodelling of cardiac hypertrophy (Wencker et 
al., 2003). Apoptosis plays a significant part in the cardiac remodelling process (Baetz et 
al.,2005). and cardiac hypertrophy and apoptosis signalling entails several lateral and assembling 
pathways (Teiger et al., 1996). Cardiac apoptosis plays an important role in controlling the shape 
and size of the heart during hypertrophy (Teiger et al., 1996).  Moreover, counteracts 
hypertrophy calcineurin-mediated NFAT activation, which is an important effector of 
hypertrophy, is critical in preventing cardiomyocyte apoptosis (Pu et al., 2003). The role of 
apoptosis in Ang-II-induced cardiac hypertrophy has lately been investigated and it was shown 
that there is an association between Ang-II, and cardiomyocyte hypertrophy and apoptosis. The 
effects of Ang-II are regulated through two G-protein-coupled receptors, AT1R and AT2R 
(Dasgupta & Zhang 2011, Da rosa Arauja et al., 2010). The AT1R is responsible for major 
physiological mechanisms of Ang-II, such as stimulation of hypertrophy and aldosterone 
secretion from the adrenal gland, vasoconstriction, cardiac contractility and growth stimulation. 
AT1R induces cardiac hypertrophy, while AT2R is believed to induce opposite effects such as 
antigrowth by apoptosis and also a possible inhibition of AT1R which subsequently will inhibit 
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1.3 Hypertrophy and apoptosis as therapeutic targets: Cardioprotection  
  
It is possible to modify the signalling pathways of apoptosis and hypertrophy to confer 
cardioprotection (Guo et al., 2010). Cardioprotection can be accomplished with the recruitment 
of endogenous mechanisms stimulated by physical or pharmacological interventions (Heusch, 
2013), or by modifying hemodynamic and neurohumoral factors of injured cardiomyoblasts. 
Cardioprotection is therefore, the artificial manipulation of cellular processes with various 
therapeutic interventions to protect the heart before, during or after disease (Maarman, 2019). 
These interventions include pre- and post-conditioning, remote ischaemic conditioning, and 
intake of antioxidants (Maarman, 2019). Over the past years, several cardioprotective strategies 
have been developed, some of which provide a powerful protection against CVD (Crowley et 
al., 2006). Other therapeutic strategies that have been examined include changes in the diet and 
medications which target the mechanisms of oxidative stress, inflammation, cardiac 
hypertrophy, fibrosis and apoptosis with, however, controversial findings (Bayeva et al., 2013; 
Papageorgiou et al., 2011). Other routine cardioprotective drugs include ACE inhibitors, 
betaadrenergic receptor blockers, (McMurray & Pfeffer, 2005), Ang-II receptor antagonists, 
warfarin, aspirin, statins, hydralazine and nitrates (Quindry and Franklin, 2018). ACE 
inhibitors and adrenergic receptor inhibitors form part of the first line of the therapeutic 
intervention in patients with heart failure. Moreover, these two therapeutic interventions also 
lower blood pressure and block left ventricular remodelling by inhibiting signalling via the 
Ang-II receptors (Hunt et al., 2009). Beta-blockers are used in conjunction with ACE inhibitors 
or adrenergic receptor antagonists to treat patients suffering with CVDs (Hunt et al., 2009).   
 
1.4 Natural cardioprotective therapies   
  
The effectiveness of cardioprotective therapies depend on the type of CVD or at the stage of 
CVDs, and their efficacy can also yield different results in different patients. Regardless of the 
success of cardioprotective pharmacologic agents in attenuating CVD, death rates among 
patients continues to rise, with about one-third of patients who die due to heart failure 
(McMurray & Pfeffer, 2005). Existing pharmaceutical drugs that are routinely prescribed to 
confer cardioprotection against CVDs have several side effects after long-term administration. 
Side effects include persistent cough, fluid retention, joint pain, hypotension, fatigue, 
depression, renal insufficiency, anaemia and headaches (Bianca C Bernardo et al., 2010). This 
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has led to a quest for alternative cardioprotective therapies, especially ones that are more natural 
as opposed to pharmaceutical (Ji et al., 2009).   
  
The search for better cardioprotective treatments has therefore placed the focus on medicinal 
plants (Maarman et al., 2020). These plants have a high polyphenol content, and are loaded 
with antioxidants (Akhlaghi and Bandy, 2009), which is what allow medicinal plants to prevent 
or alter disease processes (Mckay and Blumberg, 2007; Dludla et al., 2017). This has been 
demonstrated in experimental diabetes, inflammation, obesity, cancer/tumour growth, allergies, 
and skin conditions (Mattera et al., 2017). In recent years, great emphasis has been placed on 
medicinal plants and their ability to protect against CVDs.   
  
There has been a steep rise in the utilization of herbal remedies in the treatment of clinical 
CVDs (Vasanthi et al., 2012; Atawodi, 2005). Several medicinal plants have been declared 
helpful against CVD (Akhlaghi and Bandy, 2009) and current evidence suggests that 
approximately 80% of people in low-income countries still depend on medicinal plants for the 
treatment of CVDs (Azwanida, 2015; Ji et al., 2009). Medicinal plants have been well-known 
for their beneficial effects on health, long before their biochemical characterization (D’Andrea, 
2015). Some of the plants that have been shown to be protective against CVDs include  
Cyclopia spp. and Sutherlandia frutescens (Mckay and Blumberg, 2007; Drahansky et al., 
2016). Mainly because fewer side effects have been observed anecdotally, and due to their 
affordability even if administered long term (Azwanida, 2015; Ji et al., 2009).   
  
1.4.1 Mechanism of action in Apoptosis  
  
Another herb, Curcuma longa (Cl) commonly known as turmeric has shown to be protective 
against myocardial apoptosis (Mohanty et al., 2006). It was evaluated in an ischemia and 
reperfusion model of myocardial injury. Chronic treatment with Curcuma longa significantly 
inhibited apoptosis. The mechanism of action to attenuate apoptosis was via Bax 
downregulation and increased expression of the anti-apoptotic protein Bcl-2 as compared to 
control IR group (Mohanty et al., 2006). The herbal extract can adjust cell signalling cascades 
(Williams et al., 2004) and gene expression (Kuo, 2002; (Dong et al., 2010), in the presence of 
CVD related processes (Dludla et al., 2017). The cardioprotective effects are associated with 
an increase in cardiomyocyte survival and contractile function (Budryn et al., 2017). The 
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cardioprotection is also mediated via attenuated apoptotic signalling by reducing inflammation, 
lipid excessive increase and preventing impaired oxidation (Budryn et al., 2017). In one study 
conducted by Malkapuram et al., a hydroalcoholic extract of green coffee attenuated 
doxorubicin induced apoptosis in an H9C2 model. The data showed that green coffee is 
cardioprotective against doxorubicin-induced cardiac toxicity and this effect was mediated via 
the inhibition of apoptosis (Malkapuram et al., 2016). The extract also had cytoprotective 
effects against oxidative stress in βTC3 cells (Budryn et al., 2017). This extract of green and 
roasted coffee also applied its antioxidant properties in pro-oxidant-induced oxidative stress 
and lipid increase and utilized their bioactivity in rats fed a high-fat diet (Budryn et al., 2017).  
  
1.4.2 Mechanism of action on cardiac hypertrophy  
  
In one study conducted by Prathapan et al., 2014, Boerrhaavia diffusa L. extract also known as 
punarnava, conferred cardioprotection against impaired mitochondrial function caused by Ang-
II induced hypertrophy in H9c2 cardiomyoblasts (Prathapan et al., 2013). The group 
demonstrated that a phenolic compound of Boerrhaavia diffusa L. extract attenuated Ang-II 
induced hypertrophy, and this was mediated via reduced ROS, improved mitochondrial 
membrane potential, and improved activities of the mitochondrial ETS complexes, (Prathapan 
et al., 2013). In another study, Boerrhaavia diffusa L. extract attenuated Ang-II induced 
hypertrophy, by down-regulating NF-κB and TGF-β1 signalling (Prathapan et al., 2013). The 
extract also reduced oxidative stress via the decrease of ROS production and improved ETS 
function that improved cardiac function. Quercetin, a flavanol that occurs naturally in 
medicinal plants, has been shown to attenuate Ang-II-induced cardiac hypertrophy in H9c2 
cardiomyoblasts as well as left ventricular hypertrophy in spontaneously hypertensive rats (Yan 
et al., 2013). Quercetin inhibited hypertrophy by suppressing protein synthesis induced by 
Ang-II. It also inhibited changes in size by reducing the expression of hypertrophy markers 
(cfos, c-jun, ANP and BNP) (Yan et al., 2013).  
  
Vitexin a flavone glycoside isolated from the leaf of Crataeguspinnatifida Bunge attenuated 
isoproterenol induced cardiac hypertrophy in cultured neonatal rat ventricular myocytes in vitro 
and pressure overload-induced cardiac hypertrophy in mice (Lu et al., 2013). The pathway 
through which the cardioprotective effects of Vitexin were mediated was the calcineurin-NFAT 
pathway. Vitexin inhibited the expression of Calcineurin and NFATc3 and increased the 
expression of calmodulin kinase-II in both models (Lu et al., 2013). Rosmarinic acid (RA), one 
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of the natural polyphenol plants and ester of caffeic acid is found in mint and basil (Ito et al., 
1998) had inhibitory effects on adriamycin induced apoptosis in H9c2 cardiomyoblasts. 
Additionally, RA improved cell viability via the inhibition of intracellular ROS production and 
the restoration of cardiac mitochondrial membrane potential (Kim et al., 2005). These data 
suggest that medicinal plants are effective at counteracting CVD, and they achieve this by 
altering cardiac hypertrophy and apoptosis.   
  
1.4.3 The role of Rooibos (Aspalathus Linearis)   
  
Rooibos (RB) (Aspalathus linearis) is a member of the plant family Fabaceae that is known to 
grow in South Africa’s fynbos, it is broom-like structural. It is located to the north-western to 
western region of the Cape Floristic Region of South Africa in the Cederberg area and it is one 
of the most widely consumed herbal teas or tisanes (Mckay and Blumberg, 2007). Dating back 
to 1904, Benjamin Gunzberg recognized RB had a marketing potential and since then its 
popularity has steadily risen worldwide (Wilson, 2005). Its caffeine-free status contributed to 
the popularity of RB by modern consumers (Joubert et al., 2009). However, it was not always 
seen as advantage to be caffeine-free, in 1917 it was reported by the Imperial Institute of 
London that “It does not look like this material would be acceptable in the United Kingdom as 
a substitute for ordinary tea, as it contains no caffeine or other alkaloids and would 
subsequently not have the stimulating effect of tea’’. Later, the United Kingdom become one 
of the top importers of RB. There is another well-known export market for RB worldwide 
which include Germany, Japan, the Netherlands and the United States of America (South 
African Rooibos Council, 2017). Moreover, these countries represent more than 80% of the 
export market. RB is used as herbal infusion, health beverage, an ingredient in skin care 
products and cosmetics as well as a flavourant and colouring agent in a number of food 
applications (Windvogel, 2020).   
  
The term ‘RB’ is used to reference the plant or the herbal beverage (tea) made from the plant 
(Hawkins et al., 2011). Other than RB being used as a beverage, it is also been recognized as 
used in numerous other products such as soaps, cosmetics and skin lotions (Chuarienthong et 
al., 2010). There are several other health beneficial effects of RB. The first documented use of 
RB was during the late 1700s by local Khoi-Khoi people who were observed using the plant 
medicinally (Von Gadow et al., 1997). More than 300 years ago, the indigenous Khoi-Khoi 
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tribe of the Cedarberg and the Elephants river valley region of the Western Cape first 
discovered that the leaves of the RB plant can be used as a tea, with an exceptional taste and 
aroma (Rooibos council, 2017). Following that research began to focus more on RB and the 
health benefits of RB were confirmed. RB has gained recognition as a functional health 
beverage both local and globally, because of its unique polyphenol profile (Beltrán-Debón et 
al., 2011). It can be used in two forms, fermented and unfermented: fermented is oxidized and 
unfermented is unoxidized. The fermentation process gives fermented RB its unique brick red 
colour, while unfermented RB tea keeps its green colour (Gadow et al., 1997; Gwashu, 2016).   
  
Prior to commercialization of the “unfermented” variant, also known as green RB or 
“unfermented” RB, the name “RB” referred to the fermented product. Recent protection of the 
name “RB” in South Africa (Anonymous, 2013) and the subsequent recognition of its status as 
a geographical indication (GI) in the European Union (Anon., 2014), not only offers ownership 
of this particular name to South Africa, but it will ensure that the term will be applicable only 
to RB products. Other common names used by international markets are red bush (translation 
of RB), red RB, and red tea. The latter name can lead to confusion with other herbal teas such 
as one prepared from the leaves of the hibiscus flower. Although a misnomer, the terms 
“unfermented” and “fermented” are widely used in the context of RB (Muller et al., 2018). It 
has been shown to have anti-diabetic and hypoglycaemic effects (Jin et al., 2013; Kamakura et 
al., 2015) as well as antioxidant effects (Canda et al., 2014). In addition, RB also has 
demonstrated anti- inflammatory effects (Baba et al., 2009), it has been shown to reduce colitis 
and modulate immune function in vitro (Hendricks and Pool, 2010) as well as in vivo where it 
has been shown to promote antigen-specific antibody production through augmentation of 
interleukin-2 production (Kunishiro et al., 2001). The chemoprotective effects of RB have been 
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1.4.3 Phytochemical and nutrient content of RB  
  
Phytochemicals are non-nutritive compounds that are produced by plants and they possess 
different types of protective/ health properties (Gwashu, 2016). These phytochemicals are in 
essence, secondary plant metabolites and are mostly bound to sugar moieties that increase their 
solubility in water, thus allowing for storage in an inactive form (Perold, 2009).  The most 
common phytochemical compounds found in RB are flavonoid and phenyl pyruvic acid 
glucosides listed in Table 1 (Mckay and Blumberg, 2007). RB has anti-inflammatory, 
anticancer, antidiabetic, and antioxidant properties (Atawodi, 2005). These properties of RB 
have been ascribed to its high phytochemical content.  
  
Polyphenols can have indirect antioxidant effects altering antioxidant gene expression and 
endogenous antioxidants enzymatic defenses (Stevenson and Hurst, 2007; Forman et al., 2014). 
In a study conducted by Beltrán-Debón and colleagues, administration of RB evoked similar 
protective effects to resveratrol, the effects include improved metabolic rate and increased 
mitochondrial biogenesis (Beltrán-Debón et al., 2011). Dihydrochalcone, aspalathin and 
nothafagin are the distinct polyphenolic compounds found in RB (Dludla et al., 2016). They 
possess antithrombotic activity and also help to reduce inflammation induced by high glucose. 
Fruit and vegetables have been recognized to for their beneficial effect on human health 
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Table 1: Flavonoid and phenyl pyruvic acid glucoside content of green and fermented RB  
(Mckay and Blumberg, 2007; Walters, et al., 2017)  
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1.4.4 The link between rooibos and cardioprotection   
  
The major source of dietary phenolic consumption has been reported to reduce CVD risk 
(Mattera et al., 2017). The flavonols, Rutin and quercetin, have been proven to enhance cardiac 
function in streptozotocin-induced diabetic rats (Krishna et al., 2005). Baba et al., 2009 and 
Pantsi et al., 2011b demonstrated that fermented and unfermented RB improved aortic output 
and that this was associated with high flavonol content.   
  
RB has been reported to be anti-apoptotic due to the presence of PPAG, one of the RB 
components which has been shown to be protective against apoptosis against STZ induced 
apoptosis (Himpe et al., 2016). Beneficial effects of dietary RB extract significantly decreased 
PARP cleavage which strongly suggests that RB offers this protection by inhibiting apoptosis 
(Pantsi et al., 2011). Accumulating data have shown that flavonols inhibit apoptosis by 
downregulating the pro-apoptotic proteins, caspase-3 and Bax, in return inhibits apoptosis 
(Johnson et al., 2016; Dludla et al., 2016; Himpe et al., 2016) One study, also found that 
cardiomyoblasts pre-treated with FRE for six hours caused a reduction intracellular ROS 
production and blocked apoptosis caused by exogenous H2O2 and ischemia (Dludla et al., 
2014).  Moreover, cardioprotective effects of RB and its flavonoids also appear to involve a 
reduction in lipid peroxidation and up-regulation of the antioxidant enzymes through Nrf2 
activation, and a reduction in apoptosis which may also be associated with increases in the Bcl2: 
Bax ratio (Johnson et al., 2017; Pantsi et al., 2011b; Dludla, et al., 2017) (Table 2).  
  
Another study has reported that protective effect is dose-dependent (Kawano et al., 2009).  
Polyphenols are suggested to have pro-oxidant effect in dose response (Bennetau-pelissero, 
2005). However, the protective effect of the fermented RB extract depends on dose response 
and efficacy. Increasing the dose from 1 to 10 g/ml reduced its protective effect against 
exogenous 𝐻𝐻2𝑂𝑂2(Dludla et al., 2014). The effect of RB being dose dependent has been 
found to be interesting because one would expect that higher dose should increase its activity. 
Also, in the current study during dose-response test, a high concentration 500 µg/ml seemed to 
reduce the protective effect of RB, these finding were unexpected. In addition, it has been 
reported that polyphenols are more likely to have pro-oxidant effects at higher doses (Mennen 
et al., 2005). In addition, an aqueous extract of fermented rooibos (Aspalathus linearis) also 
demonstrated anti-diabetic effects in cardiomyoblasts.  The anti-diabetic effect was induced by 
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improving decreased of GSH and ATP concentration which are tightly related to generation of 
oxidative stress and metabolic dysfunction (Dludla et al., 2014). Several other studies have also 
reported on the anti-diabetic properties of RB. For example (Ulicna et al., 2006) showed that 
an aqueous extract of RB improved oxidative stress in streptozotocin induced Wistar rats by 
significantly lowering malondialdehyde levels in plasma and tissues of rats. In rodent models 
of streptozotocin induced diabetes, RB exerted antioxidant effects through increases in the 
activity of superoxide dismutase, catalase, glutathione peroxidase and decreasing lipid 
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Table 2: Cardioprotective effect of RB compounds in different experimental models. This 
table was designed and constructed and adapted from (Dludla, Joubert, et al., 2017)  




RB offers cardiac protection against ischaemia/reperfusion in the 
isolated perfused rat heart  
(Pantsi et al., 2011)  
Prevented cell apoptosis by reducing phosphorylation of AMPK; 
decreasing inflammation and lipid accumulation; and attenuated  




Protective properties of RB flavonoids on the prevention of skin 
cancer  
(Gwashu, 2016)  
Orientin  Prevented myocardial infarction  (Ku et al, 2014)  
and 
isoorientin  







and rutin  
Hyperoside 
and rutin  
Prevented ischemia-reperfusion injury by reducing calcium overload 
and modulating ERK1/2 signalling and MAPK pathway.  
(Che et al., 2016)  
Prevented cardiac hypertrophy by inhibiting calcineurin and CaMKII 
signalling pathways  
(Lu et al., 2013)  
Prevented ischemia-reperfusion injury and increased of coronary flow.  (Liao et al., 2011)  
Reduced arterial blood pressure and protected against 
doxorubicininduced cardiotoxicity  
(Liu et al., 2009)  
Prevented hypertensive vascular remodelling  (Su et al., 2015)  
Alleviated vascular complications associated with insulin resistance 
through the PPARγ pathway  
(El-Bassossy et al.,  
2014)  
Quercetin inhibits left ventricular hypertrophy in spontaneously 
hypertensive rats and inhibits Ang-II-induced H9C2 cells hypertrophy 
by enhancing PPAR-c expression and suppressing AP-1 activity  
(Yan et al., 2013)  
Quercetin prevents in vivo and in vitro myocardial hypertrophy through 
the proteasome-GSK-3 pathway  
(Chen et al., 2018)   
Hydrogen peroxide induced cell damage and ischemia reperfusion injury  (Li  et  al.,2012 ;   
(Piao et al., 2008)  
Protected against advanced glycation end products, oxidative stress, and 
myocardial infarction  
(Wen et al.,2013 ;   
(Hou et al., 2016)  
Attenuated ventricular remodelling associated with myocardial 
infarction  
(Ku,  Kwak  
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RB was also demonstrated to improve oxidative stress and lipid profiles after chronic 
consumption of six cups of RB tea for six weeks, these two are both associated with CVDs in 
healthy adults at risk for developing CVD (Marnewick et al., 2011). RB was also demonstrated 
to exert anti-hyperglycaemic effects. Aspalathin from green RB tea was found to prevent 
postprandial hyperglycaemia by suppressing glucose absorption and inhibiting carbohydrate 
hydrolysing enzymes (Mikami et al., 2015). Recently, Dludla and co-workers (Dludla et al., 
2020) demonstrated that RB also ameliorated glycemia-induced oxidative damage in a model 
of H9c2 cardiomyoblasts exposed to high glucose concentrations, by improving FFA 
utilization and enhanced levels of intracellular antioxidants such as glutathione and superoxide 
dismutase.  
  
RB was also demonstrated to reduce hepatic insulin resistance by modulating the PI3K/Akt and 
AMPK pathways (Mazibuko-Mbeje et al., 2019). The PI3K/Akt pathway is a complex insulin 
regulated pathway implicated in glucose and lipid metabolism. This pathway is also involved 
in other cellular processes, which include protein synthesis, cell signalling, cell growth and 
apoptosis (Huang et al., 2018; Mackenzie and Elliott, 2014).  
  
Cardiovascular protective effects of RB have also been established in several other studies. RB 
inhibited ACE in 17 healthy volunteers receiving a single oral dose of RB. This suggests that 
RB achieves cardioprotection through inhibition of ACE activity (Persson et al., 2010). It has 
been suggested that the effect of RB on ACE could be due to the presence of the double bond 
between C2 and C3, the catechol group at the B-ring and the acetone group on C4 on the Cring 
of flavonoids (Guerrero et al., 2012). The inhibition induced by RB may be due to quercetin, 
one of the RB flavonols, which has been shown to exhibit an inhibitory effect on ACE activity 
in vitro (Persson et al., 2008). ACE contains two active sites of Zn2+and therefore, the ability 
of quercetin to bind the Zn2+ ion results in the inhibition of ACE activity (Berecek and Zhang, 
1995). In an in vitro study conducted by (Persson et al., 2006) RB inhibits ACE and increases 
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1.5 Mechanisms of RB-induced cardioprotection  
  
The use of RB, particularly in its extract/tea form has become an attractive, simple and 
affordable approach to potentially treating disease (Hu, 2003; Vasanthi et al., 2012). RB extract 
has been reported to confer cardioprotection against a model of ischaemia/reperfusion in the 
isolated perfused rat heart (Pantsi et al., 2011).  Another study used RB extract to show its 
cardioprotective effect (Dludla et al., 2020) in a hyperglycemia-induced myocardial oxidative 
damaged model. Several other studies also showed cardioprotective effects of RB (Mazibuko 
et al., 2013; Smit, 2004; Mikami et al., 2015). In addition, separate RB compounds have been 
documented and proven that they may also confer cardioprotection on their own such as 
Cglucosyl flavonoids, and Z-2-(β-D-glucopyranosyloxy)-3-phenylpropenoic acid (Muller et al., 
2018), rutin (Jeong et al., 2009; Krishna et al., 2005), and quercetin (Chen et al., 2018; Panicker 
et al., 2010). However, when comparing effects of separated RB compounds on their own 
versus the whole RB extract different result effects have been shown. For example, one group 
investigated effect of quercetin, while another used RB extract against ischemia-reperfusion 
and the cardioprotective mechanisms were different. Rooibos extract prevented ischemia 
reperfusion injury by inhibiting apoptosis (Pantsi et al., 2011), while the other group using 
quercetin prevented ischemia reperfusion injury by reducing the activity of Src kinase and 
intracellular ROS production (Chen et al., 2013). Therefore, interest is accumulating to 
elucidate the underlying mechanisms of RB-induced cardioprotection. To date, these 
mechanisms have not been fully elucidated. Furthermore, despite the association between 
CVDs, hypertrophy and apoptosis, the effect of RB extract has not been investigated in a 
combined model of cardiac hypertrophy and apoptosis. Therefore, the purpose of the present 
study is to fully describe and elucidate the mechanisms of an aqueous extract of fermented RB 
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1.5.1 Hypothesis  
We hypothesize that RB confers cardioprotection in an Ang-II induced cardiomyocyte apoptosis 
and hypertrophy model.  
  
1.5.2 Aim   
  
To establish the cardioprotective effects and underlying mechanisms of RB.   
  
1.5.3 Objectives  
  
• Establish a model of Ang-II-induced hypertrophy and apoptosis using H9c2 
cardiomyoblasts  
• Investigate the cardioprotective effects of RB extract by measuring cardiomyocyte 
apoptosis, viability and cell growth/size using live cell imaging.   
• Investigate the involvement of in RB-induced mitochondrial protection by measuring 
ATP production and expression of mitochondrial ETS complexes.   
• Delineate the effect of RB on cardiomyocyte hypertrophic and apoptotic signalling 
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Chapter 2: Materials and Methods  
  
2.1 Plant material:  
A cold water-soluble RB extract 02 (fermented), batch number: E1CCJ / 23/PP/A was kindly 
supplied by Rooibos Limited® (Rooibos Avenue, Clanwilliam 8135). The procedure for 
preparation was as follows: A powdered cold-water RB extract was weighed off for each 
experiment (10mg/ml) and dissolved in a cold water to make up the stock. The dissolved extract 
was diluted freshly for each experiment in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 2% fetal bovine serum (FBS), at the acquired concentration before 
treatment for each experiment.  
  
2.2 Cell culturing and maintenance  
  
H9c2 rat embryonic heart-derived ventricular cells were originally obtained from the European 
Collection of Cell Cultures. Cells were maintained in a monolayer at 37°C and in a 95% O2,  
5% CO2, humidified air atmosphere and were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM, Invitrogen Gibco), supplemented with 10% fetal bovine serum (FBS, Invitrogen, 
Gibco) and 1% penicillin/streptomycin solution (Invitrogen, Gibco). Cells were allowed to 
proliferate in T75 flasks (75 cm2 flasks, Nest Scientific, USA) and the growth medium was 
refreshed every 72 hours. When cultures reached 70-80% confluence they were split to the next 
generation by washing the cell monolayer with pre-warmed (37°C) phosphate-buffered saline 
(PBS) followed by trypsinization using 0.25% Trypsin-ethylene-diaminetetra-acetic acid 
(trypsin-EDTA) (Invitrogen Gibco). Cells were gently agitated to ensure complete detachment 
from the flask and were transferred to a sterile tube for centrifugation at 700 rpm for 4 minutes. 
Cell pellets were re-suspended in fresh warm growth medium and a cell counter was used to 
count the cells. Cells were then seeded at the desired density in fresh warm growth medium for 
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2.3 Cell culture treatments  
  
Procedure: H9c2 cells were seeded in a 100mm petri dish at 500,000 cells per plate and 
allowed to attach and recover overnight in the incubator in a DMEM.  The next day, DMEM 
was removed and replaced with a fresh DMEM (0% FBS) for an hour and this is known as 
double starvation. After 1 h of double starvation with plain DMEM, the first group was treated 
with Ang-II added to a final concentration of 20μM, next group treated with RB (100 µM), 
Losartan (Los) only (10µM), co-treatment with RB + Ang-II and co-treatment with Ang-II + 
Los. Vehicle control cells received DMEM with 2% FBS only. The cells in all the treatment 
groups were incubated for 48 h (see Figure 6). At the end of the treatment, media was removed 
and 10 ml of fresh Dulbecco’s phosphate-buffered saline (DPBS) containing 10 µl of JC-1 dye 
as mitochondrial membrane potential indicator was added and incubated for 30min to measure 
surface area. Cells were washed with DPBS and imaged in DMEM without phenol red (Thermo 
Fisher Scientific, Paisley, UK). Live cells were imaged using a Zeiss inverted confocal 
microscope (Nikon, UK) taking a total of 6 images per treatment in 2X 100 mm petri dish 20X 
magnification. Individual images were analysed using an Image J Analyzer, ± 100 cells were 
analysed per treatment. The mean surface area per cell were measured and compared using 




2.4 Study design.  
 
  
Figure 6: Schematic representation of the study design. H9c2 cells were treated as indicated above, followed by the assessment of various 
mitochondrial and cellular parameters  
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2.5 Preparation of the drugs   
    
6.5.1 Angiotensin II Acetate human (SLBX8991) from Sigma Aldrich (MW: 1046.2) at 
1mg/ml was dissolved in 1 mL cell culture-tested water (MilliQ) to give a final concentration 
of 0.956 mM stock solution which was stored at –80°C. Working concentration of 20 and 5 
µM were made up from the initial stock using DMEM. For experimental purposes, the final 
concentration used was 20µM, as significantly increased cell size was obtained at this 
concentration compared to 5µM. Even though 5µM also increased cell size it was less effective 
than 20µM  
  
6.5.2 Losartan from Sigma (MW: 461 g/mole) at 5mg was dissolved in 10mL cell culture 
tested water (MilliQ water) to give a final concentration of 1mM stock solution which was 
stored at –80°C. Serial dilution of working concentration of 10µM was made from to initial 
stock using DMEM to make up for final concentration of 0.1µM and 1µM from 10µM. 
However, 10µM worked better as compared to other concentrations, as it significantly reduced 
increased cell sized caused by 20µM Ang-II treatment.  
  
2.5.3 JC-1 from Abcam (ab113850) (MW=652,23g/mol) at 5mg was dissolved into 2.5ml 
DMSO to give final concentration of 3mM stock solution which was stored at –80°C. The 
working concentrations for the dose-response tests were 1.65µM and 3.25µM from the initial 
stock to give dilution of final concentration 5µM and 10µM. However, we chose 10µM as it 
was more effective for the time of 30 min and analysis was much easier, while 5µM could not 
reach equilibrium in 30 min making it hard for the stain to penetrate the mitochondria. The 
incubation period 30 min found in the literature was not effective. This was due to the fact that 
it was not enough time for such a small amount of stain (5µM) to penetrate into the 
mitochondria and reach equilibrium to show the fluorescence. Thus, poor images, which were 
difficult to analyse. For that reason, we chose 10µM for 30 min. The working concentration of 
10µM was used and diluted with DPBS.  
  
2.5.4 The cold water-soluble RB extract 02 (fermented), batch number: E1CCJ / 23/PP/A 
at 10mg/ml was in dissolved 1 ml cell culture-tested water (MilliQ) stock solution stored at-
80°C. The working concentrations were 50µg/ml and 100µg/ml. However, we chose to work 
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with 100µg/ml as it was more effective when compared with 50µg/ml. The viability tests 
showed more live cells at 100µg/ml compared to 50µg/ml.  
2.6 Measurement of hypertrophic growth in H9c2 Cardiomyoblasts  
  
Hypertrophy was assayed by the measurement of cell size of H9c2 cells as previously described 
(Hwang et al., 2006; Alvarez et al., 2007). Fifty percent confluent cells were seeded at a density 
of 5x105 cells /mL in 100mm petri dish.  After treatment, cells in the 100mm petri dish plates 
were washed with PBS. 10µM JC-1 prepared in DPBS was added to each plate for 20 minutes 
at 37˚C incubation. The JC-1 solution was aspirated, and cells were washed twice with PBS. 
DPBS was then added for imaging using a Zeiss fluorescence microscope, random photographs 
were taken from each sample. Three images per sample were taken, 100 cells were selected for 
analysis to avoid biasness and images were analysed using image J for cell size.  
  
2.7 MTT Assay  
  
Cell viability assay were performed in intact H9c2 cells using the MTT cell viability assay. The 
MTT assay is a colorimetric reaction. It is also a quantitative and sensitive detection of cell 
proliferation by measuring the growth rate of cells by virtue of a linear relationship between 
cell activity and absorbance (Mahajan et al., 2012). The reduction of 3- [4, 5-dimethylthiazole2-
yl]-2, 5-diphenyltetrazolium bromide (MTT) enzyme to MTT-formazan is catalysed by 
mitochondrial succinate dehydrogenase (Chacon et al., 1997). Therefore, MTT 
cellproliferation assay measures the reduction of a tetrazolium component (MTT) into an 
insoluble formazan product by the mitochondria of viable cells.  
  
H9c2 were seeded in 24-well cell culture microplate at an optimized density of 
1.5x105cells/well and were incubated overnight at 37°C. Cells were then treated as previously 
described. At termination of treatment, medium was removed and cells were refreshed with 
200μl of Assay buffer (containing 1ml DPBS and 2mg/ml MTT assay powder) purchased from 
Sigma-Aldrich, and placed into a CO2 - free incubator at 37°C for 2 hrs, followed by addition 
of Sorensen’s buffer (01 M Glycine, 0.1M NaCl, 50 ml sterile water; pH 10.5) and DMSO to 
lyse the cells and solubilize the coloured crystals. The colorimetric detection is done at a 
wavelength of 570 nm in a spectrophotometer plate reader. Therefore, the amount of colour 
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2.8 Immunofluorescence staining  
  
Differences in mitochondrial membrane potential were detected by using 5, 5’, 6, 6’, 
tetrachloro-1, 1’, 3, 3’, -tetraethylbenzimidazolylcarbocyanine (JC-1). JC-1 is a ratiometric 
(red/green), cationic, lipophilic fluorescence probe. Due to its cationic nature, JC-1 easily 
enters the mitochondria and forms aggregates (J-aggregates) that emit red fluorescence in the 
phycoerthrin (PE - red) channel. However, in cells with decreased mitochondrial membrane 
potential or depolarized mitochondria, JC-1 remains in the cytoplasm in its monomeric form, 
which emits green fluorescence in the fluorescein (FITC - green) channel. Since the monomers 
and aggregates of JC-1 have different emission spectra, changes in mitochondrial membrane 
potential can be assessed by comparing the ratio of PE to FITC (red/green). Therefore, the ratio 
of red/green decreases as the mitochondrial membrane potential decreases (Keil et al., 2011)  
  
2.9 Measurement of aconitase   
  
Aconitase is an iron–sulfur-containing protein that isomerizes citrate and is activated during 
mitochondrial oxidative stress (Prathapan et al., 2014; Abcam, 2014). Aconitase consists of 
two isoenzymes, mitochondrial aconitase and cytosolic aconitase. The key role mitochondrial 
aconitase is to regulate ATP production through intermediate flux in the Krebs cycle.  Moreover, 
the cytosolic aconitase when in its reduced state, functions as an enzyme, while in the oxidized 
state it is implicated in regulation of iron homeostasis as iron regulatory protein 1 (IRP1). ROS 
is believed to play a critical role in the regulation of aconitase functions. Catalytic aconitase 
action is regulated by [4Fe-4S] 2+ cluster reversible oxidation and cysteine residues, so redox-
dependent posttranslational modifications (PTMs) have gained increasing consideration as 
regards possible regulatory effects. In the presence of a sustained ROS flux, redox-dependent 
PTMs are most likely to cause enzyme damage and cell stress through altered energy and iron 
metabolism.   
  
At the termination of treatment activity of aconitase was assayed in control and treated cells 
using an Aconitase assay kit (ab109712, from Abcam® USA) as per manufacturer’s 
instructions. After 48hrs of the treatment, cells were washed and gently scraped to ensure fully 
detachment and transferred into a sterile 15ml tube for centrifugation at 700 rpms, 4 min at 4˚C. 
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Cell pellets were re-suspended in fresh ice cold Aconitase preservation solution supplemented 
with 1/10 detergent and centrifuged at 20000X g for 10 minutes. Protein concentration was 
determined using the Bradford assay to determine whether the proteins extraction efficiency is 
highly variable between samples being compared. After protein determination aconitase 
activity was determined by adding 50µl of the diluted sample and 200µl of assay buffer into 
the wells of 96-well plate consist with isocitrate and manganese. Measurements were taken 
using plate reader with kinetic program for 30 minutes.  
  
2.10 ATP Activity  
  
Cell were grown and treated as previously described. ATP activity was measured using the 
luminescence-based Cell-Titre-Glo luminescence assay kit (Lonza Inc., Rockland, USA). Cells 
were cultured in 96 well plates overnight and treated for 48 hrs. Samples were prepared 
according to the manufacturer´s instructions, at the termination of the treatment 100 µl ATP 
content was added in each well for ATP levels. Measurements were performed in an iMark 
(Biorad) microplate reader, using white plate, clear bottom-bottom with lid 96 well plates, 
recording the absorbance at 450 nm after 30 min incubation at 37˚C. ATP standards were 
prepared in the range of 0.01–1 µl. Each sample and standard were prepared in triplicate in the 
assay, which was performed for each independent experiment.   
  
2.11 Fractionation of cytosol/Nucleus  
  
H9c2 cells were grown and treated as previously described in 100mm petri dishes. At the 
termination of treatment, growth medium was removed, and cells were washed with cold PBS 
(4°C). Cells were then gently scraped from the bottom of culture flasks using a sterile cell 
scraper whilst maintained on ice, and then centrifuged in a 15 ml tube at 700 rpm for 4 min at 
4˚C. The supernatant was discarded. Proteins were extracted from cell pellets by adding 200μl 
of cold Radioimmuno precipitation assay (RIPA) buffer, pH 7.4, containing: Tris-HCL 
(2.5mM), EDTA (1mM), Sodium orthovanadate (Na3VO, 1mM), Protease inhibitors (Cocktail 
of (10mg/ml)), phenyl-methyl-sulphonyl fluoride (PMSF, 0.1mM), Nonidet-P40 (NP-40, 1%), 
NaCl (0.1M).  Samples were then put on ice for 20 min to weaken the cell membranes.  After 
they have been thawed, 0.5 Zirconium beads were mixed with cells and bullet blended 3 times 
for 1 min and rested for 5 min after each spin. After bullet blending, samples were incubated 
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on ice for another 20 min and then centrifuged at 2500 rpm for 10 min (4˚C). The supernatant 
(cytosolic fraction) was transferred in a pre-cooled 2 ml Eppendorf tube. The pellets known as 
the nuclear fraction was centrifuged again to extract nuclear protein. To extract nuclear proteins, 
200μl of cold Radioimmunoprecipitation assay (RIPA) buffer plus 1% Triton and 0.1 % SDS 
were added to the cell pellets. The pellets were bullet blended as previously described to get 
nuclear extracts. After bullet blending, samples were left to rest for 20 min on ice. Samples 
were then centrifuged at 13,000 rpm for 30 minutes at 4oC. After 30 min the nuclear proteins 
in the supernatant were collected and the concentration of the proteins was determined by the 
Bradford method.  
  
2.12 Western blot  
  
Proteins were loaded and separated using gradient polyacrylamide gels with a 4% stacking gel 
(4 – 20% Mini-PROTEAN® TGX Stain-Free™ Protein Gels, Bio-Rad). A BLU eye prestained 
protein ladder (GeneDirex, PM007-0500) was loaded in the first lane on each gel as a reference 
of molecular weights of specific bands. The proteins samples were boiled for 5 min and briefly 
centrifuged before loading each sample (20μg/well) into the remaining gel lanes. Proteins were 
separated by SDS-PAGE (Criterion-PROTEAN® Tetra cell, Bio-Rad) at a constant voltage of 
100 V and current of 200 mA for 10 minutes and thereafter at a constant voltage of 140 V 
(200mA) for 50 minutes (Power Pac 1000, Bio-Rad). Following SDS-PAGE, the stain-free gels 
were imaged using the ChemiDoc™ XRS + System (Bio-Rad) to determine equal loading and 
activation of the gel. The proteins will then be transferred to a polyvinyl dine fluoride (PVDF) 
membrane (Trans-Blot® midi transfer pack, Bio-Rad) at a constant voltage of 200 V and 200 
mA for 1 hour using the Trans-Blot Turbo System (Bio-Rad). The proteins on the PVDF 
membranes were imaged using the ChemiDoc™ XRS + System (Bio-Rad).  
  
Nonspecific binding sites were blocked with 5% fat free milk in Tris-buffered saline solution 
with 0.1% Tween (pH 7.4) for 1-2 hours at 24°C. Membranes were incubated with 
Phosphospecific antibodies (1:1000) overnight at 4°C. Phospho-specific antibodies were as 
follows: Phospho-mTOR (Ser2448), Phospho-GSK-3 beta (Ser 9), phospho-PKB/ Akt (Ser-
473), phospho-ERK1/2 or p44/p42 (Thr-202/Tyr-204) Phospho-p38 (Cell Signalling, Danvers, 
MA, USA). The corresponding antibodies for total protein expression (1:2000) were also used:  
mTOR, GSK-3 beta, PKB/Akt, ERK1/2 or p44/p42, as well as Calcineurin A/B, 3, Caspase-3, 
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Bax, Bcl-2, and p38 MAPK. Histone was also used as nuclear marker. After incubation with 
horseradish peroxidase-linked secondary antibody (1:2000 to 1:5000), signals were enhanced 
with a chemiluminescent agent (ECL) and visualized by ChemiDoc using Image Lab. Results 
were normalized to the total protein loaded via the house-keeping protein beta tubulin, to 
correct for unequal loading and expressed as a ratio of phosphorylated over total proteins. For 
each gel, all values were expressed as a fold-change to the untreated control samples. For each 
gel there were 6 groups, and all were loaded in duplicate. We also did three biological repeats.  
  
2.13 Quantification of individual flavonoids   
  
High performance liquid chromatography (HPLC) analysis with diode-array detection as 
previously described on an Agilent 1200 system (Agilent, Santa Clara, CA, USA) was used to 
determine the compounds present in the fermented rooibos extract. All the compounds were 
determined using the method described in Walters et al.  (2017). However, Aspalathin and 
ferulic acid were determined using the method described in (Muller et al., 2020).  
  
The peak height or area for different peaks cannot be compared directly as different compounds 
have different spectra with different wavelengths for maximum absorbance. We use 288 nm 
for compounds with maximum absorbance near 288 nm (e.g. PPAG, Aspalathin), while 350 
nm is used for compounds with their maximum absorbance near 350 nm (e.g. orientin and 
isoorientin). Furthermore, compounds with their maximum absorbance at a similar wavelength 
could still have different extinction coefficients, i.e. different concentrations of the compound 
are needed to give the same peak area. Therefore, we used authentic reference standards to 
generate calibration curves against which each compound is quantified.  
  
2.14 Statistical Analysis  
  
Statistical analysis was performed using GraphPad Prism software (GraphPad Software, Inc.). 
Comparisons between treatment groups were performed using a one-way ANOVA analysis 
followed by a Bonferroni multiple comparison as a post hoc test or an unpaired Student’s t-test 
where appropriate. A P-value of ≤0.05 was deemed as statistically significant. Results were 
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Chapter 3: Results  
  
3.1 Ang-II induces cardiomyocyte hypertrophy/apoptosis in a dose-dependent 
manner  
  
Cardiomyoblasts were stimulated with either 5 µM Ang-II or 20 µM for 48 h before analysis 
of changes in cell morphology. To study the dose–response effect of Ang-II on cardiomyocyte 
hypertrophy/apoptosis, H9c2 cardiomyoblasts were exposed to various concentrations of AngII, 
and hypertrophy/apoptosis was estimated 48 h after culture by JC-1 Staining (Figure 7). The 
results showed that the pro-hypertrophy and pro-apoptotic effect of Ang-II on cardiomyocyte 
viability was gradually enhanced between 0.1 and 20 µM, and Ang-II at 20µM appeared to 
have the strongest action. The concentration of 20mM was therefore chosen for Ang-II for the 
subsequent experiments (Figure 8).  
 
 
Figure 7: Ang-II induced hypertrophic growth of H9C2 cells. Dose–response effect of 
ANGII on cardiomyocyte hypertrophy, H9c2 cardiomyoblasts were exposed to two 
concentrations of ANGII (5µM & 20µM), and hypertrophy was estimated 48 h after culture by 
JC-1 Staining. The yellow borders delineate the size of the cell. A bright field microscope was 
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Figure 8: Ang-II induce hypertrophy in a dose-dependent manner. After treated with Ang-
II (5 and 20µM) alone for 48 h. Ang-II induced hypertrophy in a dose-dependent manner and 
20 µM proved to be more effective as compared to 5µM.The experiments had three biological 
repeats (n=3), each of the three repeats had two technical repeats. The values denote the 
average area ± SEM; *P < 0.05.  
.   
3.2 Rooibos extract HPLC analysis  
  
Our HPLC analysis of the extract showed high levels of the flavonoids iso-orientin (0.396 g/100 
g), orientin (0.515 g/100 g), Bioquercetin (0.455 g/100 g) and as well as the flavanone Z-2-(β-
D-glucopyranosyloxy)-3-phenylpropenoic acid (PPAG), (0.421 g/100 g), (R)-8-β-
Dglucopyranosyl-eriodictyol (0.221g/100g), (S)-8-β-D-glucopyranosyl-eriodictyol 
(0.225g/100g), (R)-6-β-D-glucopyranosyl-eriodictyol (0.269g/100g), (S)-6-β-
Dglucopyranosyl-eriodictyol (0.284g/100g) (Table 3). However, other flavonoids i.e. 
Aspalathin, nothofagin, vitexin, hyperoside, rutin, isovitexin, isoquercitrin and luteolin-7-
Oglucoside, and ferulic acid were present at less than 0.2 g/100 g plant material.   
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Table 3: soluble solids content (g/100g plant material) of fermented rooibos plant 
material. The data represent means.  
  
Compounds  Numbers  Concentration [compound] (g 
compound/100 g SS)  
(S)-6-β-D-
glucopyranosyleriodictyol  
1  0,284  
(R)-6-β-D-
glucopyranosyleriodictyol  
2  0,269  
(S)-8-β-D-
glucopyranosyleriodictyol  
3  0,225  
(R)-8-β-D-
glucopyranosyleriodictyol  
4  0,221  
Z-2-(β-
Dglucopyranosyloxy)-
3phenylpropenoic acid  
(PPAG)  
5  0,421  
Isoorientin  6  0,396  
Orientin  7  0,515  
Aspalathin  8  0,161  
Ferulic acid  9  0,030  
Bioquercetin  10  0,445  
Vitexin  11  0,164  
Hyperoside  12  0,120  
Rutin  13  0,101  
Isovitexin  14  0,074  
Isoquercitrin  15  0,071  
Luteoloside  16  0,115  
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Figure 9: HPLC for fermented cold-water rooibos extract. High performance liquid 
chromatography diode-array detection chromatograms for fermented cold-water rooibos 
extract obtained using the developed method described by (Villiers, et al., 2017) and (Muller 
et al., 2020) at 288 nm and 350 nm wavelengths. Peak numbers correspond to numbers in  
Table 3.     
3.2 Toxicity dose-response of Rooibos  
  
The potential cytotoxicity of Rooibos was analysed using a cell viability assay (MTT Assay). 
H9c2 cells were incubated with various concentrations of Rooibos (50, 100 or 500μg/ml) for 
48 h. Cell viability in Rooibos-treated cells exhibited no significant differences when compared 
with the control cells, indicating that Rooibos at these concentrations did not possess any 
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Figure 10: The effects of Rooibos (RB) on H9c2 cardiomyoblasts. RB toxicity was measured 
in H9c2 cells 48 hrs. RB toxicity was measured using MTT Assay. The data was represented 
using ANOVA, n=4.The experiments were repeated three times (n=3), with each repeat done 
in duplicate. The values denote the average area ± SEM; ## P < 0.01; *** P < 0.001  
    
3.3 RB decreased Cell Surface Area in Hypertrophic Cardiomyoblasts  
  
The inhibitory effect of RB in hypertrophic cardiomyoblasts was investigated by measuring 
cell size after cells were exposed to RB + Ang-II co-treatment. The duration of the treatment 
was 48 hrs with Ang-II (20µM) in the presence or absence of losartan (Los) or RB. (A) 
Representative average area of four individual experiments.   
The cell surface area significantly increased after 48 h stimulation with 20µM Ang-II (Figure 
11). The cell area of the control group was increased from 1931 ± 78.04µm2 to 2389 ± 
104.9µm2 after treatment with Ang-II (n=4, p<0.05; Figure 12). Measurement of the area of 
the cells after treatment with RB (100μg/ml) revealed that RB decreased the Ang-II induced 
increased growth from 2389 ± 104.9µm2 to 1886 ± 30.37µm2. (n=4, p<0.01) Moreover, a 
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the cell area from 2389 ± 104.9µm2 to 1931 ± 40.38, (n=4, p<0.05). Compared with the control 
group, we found that the area of cells treated with RB and Los only were not increased, there 
was no significant difference.  
 
Figure 11: Ang-II induced hypertrophic growth of H9C2 cells was inhibited by Rooibos 
(RB). Representative images of individual cells conditions. (i) control cells, (ii) Rooibos, (iii) 
Losartan, (iv) Ang-II, (v) RB+ Ang-II, Los+ Ang-II, (vi) RB + RB. The yellow borders delineate 
the size of the cell. Microscopic observation of hypertrophy formation following increase in 
cell size (original magnification 20X). After treated with RB (100 µg/ml) and Ang-II (20µM) 
alone or in combination for 48 h. H9C2 cells were stained with JC-1, hypertrophy was analysed 
by measuring cell surface area using Image J software 7.0.  
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Figure 12: Rooibos inhibited Ang-II induced hypertrophic growth of H9c2 cells. 
Quantification of cell size change. Ang II (20µM) caused an increase in H9c2 cell size and was 
attenuated by RB (100µg/mL). The values denote the average area ± SEM (n = 4) with 
duplicate determinations in each experiment. (* P < 0.05; ** P < 0.01)   
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3.4 RB prevents Cell death in Hypertrophic/Apoptotic Cardiomyoblasts  
  
Cells treated with Ang-II only and those treated with RB + Ang-II was evaluated for viability. 
Our results have shown that Ang-II decreased cell viability in apoptotic cells. Our results 
revealed that treatment with RB extract protected the cells from Ang-II-induced cell death. The 
viability significantly increased after treatment with RB. RB had similar effect as the Ang-II 
receptor inhibitor, Los.   
 
  
Figure 13: The cardioprotective effect of Rooibos (RB) investigated on cell viability. Cell 
viability was measured in H9c2 cells 48 hrs after treatment with Ang-II (20µM). Cell viability 
test showed that RB increased cells’ viability when compared to Ang-II treated group. Cell 
viability was measured using MTT Assay. The data was represented using ANOVA, n=4. The 
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3.5 Western blot  
3.5.1 Effect of RB in hypertrophic signalling pathways   
  
Western Blotting was performed on H9c2 cells treated with the RB, Ang-II, Losartan classical 
inhibitor of Ang-II, to measure the expression and activation of important hypertrophy 
signalling intermediates such as PKB, GSK-3β, ERK 1/2 and mTOR. The expression of 
Calcineurin was also determined in H9c2 cells. For each gel, all values were normalized to 
Btubulin, expressed as a fold-change to the untreated control samples and presented as mean ± 
SEM All the blots were repeated three times. Each blot used for display represents one of the 
three biological repeats. Each biological repeat is blotted in duplicate.   
  
3.5.1.1 RB increases the Activity of GSK-3ß in Hypertrophic/Apoptotic H9c2 cells  
  
GSK-3ß is also known as one of the important inducers of cardiac hypertrophy (Antos et al., 
2002; Hardt & Sadoshima, 2002). To determine whether the phosphorylation of GSK-3ß was 
involved in development of Ang-II-induced cardiac hypertrophy we used western blot 
measured by phosphorylated specific antibody (Figure 14). Compared to the control, the level 
of phosphorylated GSK-3ß was increased in the Ang-II-treated group, but this increase was 
blocked by RB treatment. Additionally, there was no significant difference in total GSK-3ß 
between control and the Ang-II group (Figure 15). Also, no significant difference was observed 
after RB treatment and Ang-II group in total GSK-3ß. The Ratio of phosphorylated vs. total 
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Figure 14: Effect of RB on phosphorylated-GSK-3β levels in Ang-II induced hypertrophy. 
H9c2 cells were treated for 48 hrs with Ang-II (20µM) in the presence or absence of Rooibos 
(100μg/ml) or Losartan (10µM). Each experiment was repeated three times in H9c2 
cardiomyoblasts. Representative Western blot of phosphorylated GSK-3β and beta-tubulin. 
This blot represents one of the three biological repeats, each is in duplicate.  All values were 
normalized to beta-tubulin, expressed as a fold-change to the untreated control samples and 
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Figure 15: Effect of RB on total-GSK-3β protein expression in hypertrophy/Apoptotic 
cells. H9c2 cells treated for 48 hrs with Ang-II (20µM) in the presence or absence of Rooibos 
(100μg /ml) or Losartan (10µM). Each experiment was repeated three times in H9c2 
cardiomyoblasts. Representative Western blot of Total GSK-3β and beta-tubulin. This blot 
represents one of the biological repeats (n=3) in the appendix, each biological repeat is in 
duplicate. All values were normalized to beta-tubulin, expressed as a fold-change to the 
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Figure 16: Effect of RB on Phosphorylated/Total-GSK-3β ratio expression in 
hypertrophy/Apoptotic cells. H9c2 cells treated for 48 hrs with Ang-II (20 µM) in the 
presence or absence of Rooibos (100μg/ml) or Losartan (10µM). Each experiment was 
repeated three times in H9c2.  The data is presented as mean ±SEM. * P < 0.05  
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3.5.1.2 RB inhibit phosphorylation of PKB/Akt  
  
Several intracellular signalling pathways have been reported to play a role in the promotion of 
cardiac hypertrophy, these include PKB/Akt pathway. To confirm that PKB was activated in 
response to a model of Ang-II induced hypertrophy, we assessed the phosphorylation of 
PKB/Akt pathway by western blotting with phosphorylated specific antibody (Figure 17). We 
found that Ang-II increased phosphorylation of PKB/Akt. However, the increased 
phosphorylation was downregulated by treatment with RB + Ang-II co-treatment. We also 
found that when RB alone is compared with the control group there was no significant 
difference (Figure 18). Same results were observed with Losartan an Ang-II classical inhibitor. 
The Ratio of phosphorylated vs. total PKB in cardiomyoblasts from the Ang-II treated cells 
significantly increased when treated with RB (Figure 19). 
Figure 17: Effect of RB on Phospho-PKB protein levels in Ang-II-induced hypertrophy. 
H9c2 cells treated for 48 hrs with Ang-II (20µM) in the presence or absence of Rooibos (100μg/ml) 
or Losartan (10µM). Each experiment was repeated three times in H9c2 cardiomyoblasts. 
Representative Western blots of Phosphorylated and beta-tubulin. Each blot represented above 
represents one of the three biological repeats, each biological repeats the treatments are in 
duplicates. All values were normalized to beta-tubulin, expressed as a fold-change to the 
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Figure 18: Effect of RB on total PKB protein expression in Ang-II-induced hypertrophy. 
H9c2 cells treated for 48 hrs with Ang-II (20µM) in the presence or absence of Rooibos (100μg 
/ml) or Losartan (10µM). Each experiment was repeated three times in H9c2 cardiomyoblasts. 
Representative Western blot of Total PKB/Akt and beta-tubulin. Each blot represented above 
represent one of the three biological repeats, each biological repeat are in duplicates. All 
values were normalized to beta-tubulin, expressed as a fold-change to the untreated control 
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Figure 19: Effect of RB on Phosphorylated/total-PKB ratio expression in 
hypertrophy/apoptotic cells. H9c2 cells treated for 48 hrs with Ang-II (20µM) in the presence 
or absence of Rooibos (100μg /ml) or Losartan (10µM). Each experiment was repeated three 
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3.5.1.3 Effect RB on Ang-II stimulated phosphorylation of ERK1/2  
  
The stimulation of cells with Ang-II provoked an increase in the expression of ERK1/2. This 
effect was attenuated by RB from 1.879 ± 0.114 to 1.419 ± 0.123 (Figure 20).  We also found 
that Losartan significantly inhibited increased phosphorylation by Ang-II. There was no 
significant difference between Ang-II and RB + Ang-II co-treatment in total expression (Figure 
21). The Ratio of phosphorylated vs. total ERK 1/2 showed no significant differences in the 
cells from the Ang-II treated and RB co-treated cells (Figure 22).   
 
Figure 20:  Effect of RB on phospho-ERK1/2 protein levels in hypertrophy/Apoptotic cells. 
H9c2 cells treated for 48 hrs with Ang-II (20µM) in the presence or absence of Rooibos (100μg 
/ml) or Losartan (10µM). Each experiment was repeated three times in H9c2 cardiomyoblasts. 
Representative Western blot of Phosphorylated ERK 1/2 and beta-tubulin. This blot above is 
one of the three biological repeats (n=3) with two technical repeats for each biological repeat. 
All values were normalized to beta-tubulin, expressed as a fold-change to the untreated control 
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Figure 21:  Effect of RB on total-ERK1/2 protein expression in hypertrophy/Apoptotic 
cells. H9c2 cells treated for 48 hrs with Ang-II (20µM) in the presence or absence of Rooibos 
(100μg /ml) or Losartan (10µM). Each experiment was repeated three times in H9c2 
cardiomyoblasts. Representative Western blot of Total ERK 1/2 and beta-tubulin. This blot 
above is one of the three biological repeats (n=3) each technical repeat is in duplicates. All 
values were normalized to beta-tubulin, expressed as a fold-change to the untreated control 










   70  
    
 
  
Figure 22:  Effect of RB on Phosphorylated/Total-ERK1/2 ratio levels in 
hypertrophy/Apoptotic cells. H9c2 cells treated for 48 hrs with Ang-II (20µM) in the 
presence or absence of Rooibos (100μg /ml) or Losartan (10µM). Each experiment was 
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3.5.1.4 Effect of RB on mTOR expression  
  
The expression of mTOR was evaluated and the results showed that the phosphorylation of 
mTOR protein was significantly unregulated in the hypertrophy induced by Ang-II. However, 
after adding RB, we found that RB co-treatment could significantly downregulate the increased 
phosphorylation levels of mTOR protein induced by Ang-II (Figure 23). In addition, we also 
found that Losartan Ang-II inhibitor could also significantly downregulate the expression of 
mTOR. We also found same trend with Losartan, it significantly attenuated increased 
phosphorylation by Ang-II. We also observed a significant decrease in mTOR levels when 
compared to the control group (Figure 23). We found no significant difference in total mTOR 
expression (Figure 24). The ratio of phosphorylated vs. total mTOR in the Ang-II treated cells 
significantly increased when exposed to RB co-treatment (Figure 25).  
 
Figure 23: Effect of RB on Phospho-mTOR protein levels in Ang-II induced hypertrophy. 
H9c2 cells treated for 48 hrs with Ang-II (20µM) in the presence or absence of Rooibos 
(100μg/ml) or Losartan (10µM). Each experiment was repeated three times in H9c2 
cardiomyoblasts. Representative Western blot of Phosphorylated mTOR and beta-tubulin. This 
blot above is one of the three biological repeats (n=3) each is in duplicate. All values were 
normalized to beta tubulin, expressed as a fold-change to the untreated control samples and 
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Figure 24: Effect of RB on total-mTOR protein expression in Ang-II-induced 
hypertrophy. H9c2 cells treated for 48 hrs with Ang-II (20µM) in the presence or absence of 
Rooibos (100μg /ml) or Losartan (10µM). Each experiment was repeated three times in H9c2 
cardiomyoblasts. Representative Western blots of Total mTOR and beta-tubulin. The blot 
above represents one of the three biological repeats (n=3) with two technical repeats. All 
values were normalized to beta-tubulin, expressed as a fold-change to the untreated control 
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Figure 25: Effect of RB on Phosphorylated/total-mTOR ratio expression in hypertrophy. 
H9c2 cells treated for 48 hrs with Ang-II (20µM) in the presence or absence of Rooibos 
(100μg/ml) or Losartan (10µM). Each experiment was repeated three times in H9c2 
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3.5.1.5 RB down-regulated phosphorylation of Calcineurin  
  
We investigated the possible involvement of Calcineurin–NFAT pathway in the 
cardioprotective activity of RB against ANGII-induced cardiac hypertrophy using specific total 
calcineurin antibody. We observed an increase in expression in Ang-II-treated cells compared 
to the control. However, we found that after treatment with RB co-treatment the increased 
expression of calcineurin was downregulated. We observed that Losartan also down-regulated 
the increase in calcineurin caused by Ang-II (Figure 26).  
 
 
Figure 26: Effect of RB on Calcineurin protein expression in Ang-II-induced hypertrophy. 
H9c2 cells treated for 48 hrs with Ang-II (20µM) in the presence or absence of Rooibos 
(100μg/ml) or Losartan (10µM). Each experiment was repeated three times in H9c2 
cardiomyoblasts. Representative Western blot of Calcineurin expression and beta-tubulin. The 
blot above represents one of the three biological repeats (n=3) each is in duplicate. All values 
were normalized to beta-tubulin, expressed as a fold-change to the untreated control samples 
and presented as mean ± SEM (n=3). * P<0.05.  
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3.5.2 Effect of RB in apoptotic pathways  
  
To confirm which of the pro-apoptotic and anti-apoptotic proteins were activated in Ang-II 
induced apoptosis, we used western blot to measure the expression and activation of the 
following apoptotic signalling intermediates such as Bax, Caspase-3, P38 and Bcl-2, Bax/Bcl2. 
The results showed that compared with the control group apoptosis was increased in the Ang-
II-treated group. However, RB inhibited the apoptosis induced by Ang-II. All values were 
normalized to beta-tubulin. The experiment was repeated three times. Each of the blots below 
represents one of the three biological repeats (n=3) in the Appendix, with each repeat consisting 
of two technical repeats.  
3.5.2.1 Effect of RB on Bax expression  
  
The H9c2 cells from the Ang-II treated group showed significantly up-regulated protein 
expression of the Apoptotic executor Bax when compared to the cardiomyoblasts from control 
group from the 1.000 ± 0.278 to 1.850 ± 0.394 to 1.617 ± 0.183. Furthermore, the cells after 
treatment with RB presented with significantly decreased expression of Bax from 1.617 ± 0.183 
to 0.674 ± 0.250 (Figure 27).  
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Figure 27:  Effect of RB on Bax in H9c2 cells. H9c2 cells treated for 48 hrs with Ang-II 
(20µM) in the presence or absence of Rooibos (100μg/ml) or Losartan (10µM). Each 
experiment was repeated three times in H9c2 cardiomyoblasts. Representative Western blots 
of Bax expression and beta-tubulin. The blot above represents one of the biological repeats 
(n=3) in the Appendix, with each biological repeat with two technical repeats. All values were 
normalized to beta tubulin, expressed as a fold-change to the untreated control samples and 
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3.5.2.2 Effect of RB co-treatment on Bcl-2 expression  
  
The expression of Bcl-2 was significantly downregulated in the Ang-II-treated group. On the 
other hand, RB co-treatment significantly prevented the down-regulation of Bcl-2 compared to 
Ang-II stimulated cells (Figure 28).  
 
Figure 28: Effect of RB on Bcl-2 in H9c2 cardiomyoblasts. H9c2 cells treated for 48 hrs 
with Ang-II (20µM) in the presence or absence of Rooibos (100μg /ml) or Losartan (10µM). 
Each experiment was repeated three times in H9c2 cardiomyoblasts. Representative Western 
blot of Bcl-2 and beta-tubulin. The blot above represents one of the biological repeats (n=3) in 
the Appendix, with each biological repeat with two technical repeats. All values were 
normalized to beta-tubulin, expressed as a fold-change to the untreated control samples and 
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3.5.2.3 Effect of RB co-treatment in the Bax/Bcl-2 ratio  
  
The results demonstrated that the expression of Bax/Bcl-2 ratio was significantly upregulated 
in the Ang-II treated cells. However, after addition of RB, we found that RB could significantly 
downregulate the expression of Bax/Bcl-2 ratio (Figure 29).  
 
Figure 29: Effect of RB on Bax/Bcl-2 ratio in H9c2 cells. H9c2 cells treated for 48 hrs with 
Ang-II (20µM) in the presence or absence of Rooibos (100μg /ml) or Losartan (10µM). Each 
experiment was repeated three times in H9c2 cardiomyoblasts. Representative Western blot of 
Bax/Bcl-2 expression and beta-tubulin. The blot above represents one of the biological repeats 
(n=3) in the Appendix, with each biological repeat with two technical repeats. All values were 
normalized to beta-tubulin, expressed as a fold-change to the untreated control samples and 
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3.5.2.4 Effect of RB on Caspase-3 expression   
  
The H9c2 cardiomyoblasts from the Ang-II treated group showed a significant increase in the 
basal expression of Apoptotic executor cleaved caspac-3 when compared to the cells from 
control group from 1.000 ± 0.278 to 1.85 ± 0.394. However, co-treatment with RB mitigated 
the increased cleavage of caspase-3 from 1.85 ± 0.394 to 1.146 ± 0.03.   
 
 
Figure 30:  Effect of RB on Cleaved caspase-3 in H9c2 cells. H9c2 cells treated for 48 hrs 
with Ang-II (20µM) in the presence or absence of Rooibos (100μg /ml) or Losartan (10µM). 
Each experiment was repeated three times in H9c2 cardiomyoblasts. Representative Western 
blots of Cleaved caspase expression and beta-tubulin. This blot represents one of the three 
biological repeats (n=3), each biological repeat has two technical repeats. All values were 
normalized to beta-tubulin, expressed as a fold-change to the untreated control samples and 
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3.5.2.5 Inhibitory effect of RB on up regulated p38 levels  
  
In order to prove whether the anti-apoptotic effect of RB is mediated via p38 MAPK, expression 
level of p38 MAPK and phosphorylated p38 were also analysed in treated cells and control. 
Ang-II induced a rapid increase in the phosphorylation of p38 when compared to the control. 
However, Ang-II-induced phosphorylation was inhibited by RB from 1.492 ± 0.1387 to 0.5038 
± 0.07465 (Figure 31). We did not observe any notable difference in the expression of total p38 
MAPK in both control and treated cells (Figure 32). The ratio of phosphorylated vs. total P38 
showed no significant differences in the cardiomyoblasts from the Ang-II treated and RB 
treated cells (Figure 33).  
 
Figure 31: Effect of RB on Phosphorylated p38, in H9c2 cardiomyoblasts. H9c2 cells 
treated for 48 hrs with Ang-II (20µM) in the presence or absence of Rooibos (100μg /ml) or 
Losartan (10µM). Each experiment was repeated three times in H9c2 cardiomyoblasts. 
Representative Western blot of Phosphorylated p38 and beta-tubulin. This blot represents one 
of the three biological repeats (n=3), each biological repeat has two technical repeats. All 
values were normalized to beta-tubulin, expressed as a fold-change to the untreated control 
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Figure 32: Effect of RB on t-p38 in H9c2 cells. H9c2 cells treated for 48 hrs with Ang-II 
(20µM) in the presence or absence of Rooibos (100μg /ml) or Losartan (10µM). Each 
experiment was repeated three times in H9c2 cardiomyoblasts. Representative Western blots 
of Total p38 and beta-tubulin. The blot above represents one of the three biological repeats 
(n=3). All values were normalized to beta-tubulin, expressed as a fold-change to the untreated 
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Figure 33: Effect of RB on Phosphorylated/total-p38 ratio in H9c2 cells. H9c2 cells treated 
for 48 hrs with Ang-II (20 µM) in the presence or absence of Rooibos (100μg /ml) or Losartan 
(10µM). Each experiment was repeated three times in H9c2 cardiomyoblasts. The data was 
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3.6 Effect of RB on metabolic activity  
  
3.6.1 Mitochondrial membrane potential  
  
In this present study we determined whether RB exerts its protection on mitochondria. Ang-II 
at 20 µM caused a remarkable and statistically significant decrease in JC-1 ratio in Ang-
IItreated group indicating a loss of mitochondrial membrane potential. JC-1 in the untreated 
group was 1.53 ± 0.38 and that was decreased to 0.44 ± 0.05 upon addition of Ang-II. Evidence 
in the present study indicate that RB co-treatment significantly restored mitochondrial 
membrane potential and JC-1 ratio to 0.92 ±0.186, this indicated positive activity of RB against 
Ang-II induced mitochondrial toxicity (Figure 34). This was statistically significant compared 
to Ang-II-treated group.   
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Figure 34: Effect of RB on mitochondrial membrane potential in hypertrophy/apoptotic cells. 
The representative images show JC-1 aggregates, JC-1 monomers and merged images of both. (a) 
Control cells, (b) Rooibos, (c) Losartan, (d) Ang-II, (e) Los + Ang-II, (f) RB + Ang-II. The cell is 
stained with JC-1, then analysed with Image J software to determine mitochondrial membrane 
potential.20X magnification was used to take pictures.  
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Figure 35: Change in mitochondrial membrane potential in different groups. (Ratio of JC-
1 aggregates (Red) to JC-1 monomers (Green). The graph represents the ratio of JC-1 
aggregates to JC-1 monomers (ratio of 590:530 nm emission intensity) demonstrate alteration 
of membrane potential Ang-II while maintenance by RB. The values are fold-changes to 
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3.6.2 ATP Activity   
  
The results showed that ATP levels in the Ang-II-treated cells were decreased by 37% 
compared with the control group. Comparison between the RB co-treated cells and Ang-II 
treated cells the results revealed that the ATP level was increased by 21% (Figure 36).  
 
Figure 36: Effect of RB on the ATP activity in Ang-II-induced hypertrophy/apoptosis. 
Cellular viability was measured using Cell-Titre-Glo luminescence assay kit. Relative light 
unit (RLU). The experiments were repeated three times. Data presented as mean ± SEM.* 
P<0.05, ** P<0.01.  
    
3.6.3 Mitochondrial respiratory complexes  
  
The expression of respiratory chain complexes such as complexes IV and V were significantly 
decreased in Ang-II treated cells compared to control cells. There were reductions in expression 
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reduction in the expression of the respiratory chain complexes compared to the Ang-II-treated 
cells (Figure 40 & 41). In addition, we found no significant difference in complex II and III 
between co-treated RB and Ang-II treated cells (Figure 38, 39). We further found that complex 
II & IV were significantly difference in RB only compared to the control (Figure 36, 38). We 
also observed that complex III, IIV & V were significantly different in Losartan alone compared 
to the control (Figure 37, 38 & 39). All these values are fold-changes to untreated controls.  
 
 
Figure 37: Effect of RB on mitochondrial complex chain. H9c2 cells treated for 48 hrs with 
Ang-II (20µM) in the presence or absence of Rooibos (100μg /ml) or Losartan (10µM). Each 
experiment was repeated three times in H9c2 cardiomyoblasts. The blot represents one of the 
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Figure 38: Effect of RB on complex II. Graphical representation of complex II. H9c2 cells 
treated for 48 hrs with Ang-II (20µM) in the presence or absence of Rooibos (100μg /ml) or 
Losartan (10µM). Each experiment was repeated three times in H9c2 cardiomyoblasts. The 
data was presented as mean ± SEM (n=3). *P<0.05  
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Figure 39: Effect of RB on complex III expression. Graphical representation of complex III. 
H9c2 cells treated for 48 hrs with Ang-II (20µM) in the presence or absence of Rooibos 
(100μg/ml) or Losartan (10µM). Each experiment was repeated three times in H9c2 
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Figure 40: Effect of RB on complex IV expression. Graphical representation of complex IV. 
H9c2 cells treated for 48 hrs with Ang-II (20µM) in the presence or absence of Rooibos 
(100μg/ml) or Losartan (10µM). Each experiment was repeated three times in H9c2 
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Figure 41: Effect of RB on complex V expression. Graphical representation of complex VI. 
H9c2 cells treated for 48 hrs with Ang-II (20µM) in the presence or absence of Rooibos 
(100μg/ml) or Losartan (10µM). Each experiment was repeated three times in H9c2 
cardiomyoblasts. The data was presented as mean ± SEM (n=3). *P<0.05, **P<0.01  
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7.7 Effect of RB on Aconitase activity  
Aconitase activity was measured using the Aconitase assay kit at an absorbance of 240 nm. To 
determine catalytic activity of Aconitase the conversion of the substrate isocitrate to 
cisaconitate was measured as an increase in absorbance over a period of 30 minutes (Figure 
42). The results showed no significant difference in Aconitase activity in Ang-II treated cells, 




Figure 42: Effect of RB on aconitase activity. Representation of Aconitase activity over a 
30-minute time period. The experiment was repeated three times with two technical repeats for 
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Chapter 4: Discussion  
  
In the current study we investigated the cardioprotective effects of RB in an H9c2 model of 
Ang-II-induced hypertrophy and apoptosis. We have provided evidence that Ang-II in fact did 
cause hypertrophy (Prathapan et al, 2014; Li et al., 2017) and apoptosis (Liu et al., 2009; Pang 
et al., 2004) as reported previously. Firstly, apoptosis induced by Ang-II was observed as 
decreased cell viability, up-regulation of pro-apoptotic markers Bax, caspase-3 and 
downregulation of anti-apoptotic Bcl-2. Secondly, Ang-II stimulated hypertrophy was 
validated by observing increased cell size and upregulating growth signalling pathways. 
Thirdly, Ang-II reduced the expression of mitochondrial complexes IV and V, decreased 
mitochondrial membrane potential and reduced cellular ATP content. RB co-treatment 
effectively antagonized Ang-II-induced apoptosis and hypertrophy of H9c2 cells. This was 
mediated by increasing Bcl-2, decreasing Bax and caspase-3, reducing cell size and increasing 
cell viability. RB dephosphorylated growth signalling pathways such as ERK 1/2, PKB, mTOR, 
Calcineurin and GSK-3ß. Lastly, RB improved mitochondrial membrane potential, increased 
ATP content and restored expression of mitochondrial complexes IV and V.   
  
A cold-water RB extract was used in this study, and our HPLC analysis showed that the major 
flavonoid in our extract was Aspalathin (0.161g/100g). Aspalathin and its 3-deoxy derivative 
nothofagin (0.020g/100g), as well as their flavone derivatives, isoorientin (0.396g/100g), 
orientin (0.515g/100g), vitexin (0.164) and isovitexin (0.074g/100g) comprised 1.33g/100g of 
the extract. The major quercetin glycoside was bioquercetin (quercetin-3-O-robino-bioside; 
0.445g/100g) as well as the phenolic precursor Z-2-(β-D- glucopyranosyloxy) 
−3phenylpropenoic acid which was (0.421g/100g). We also quantified the flavanones 
compound 1-4. Other compounds being quantified included luteoloside (a flavone) and 
quercetin glycosides (rutin, hyperoside and isoquercitrin), all present at levels less or equal to 
one, in the extract. HPLC analysis of fermented RB extract showed that our extract contained 
high levels of Z-2-(β-D- glucopyranosyloxy) −3-phenylpropenoic acid (PPAG) and the 
flavonoids isoorientin, orientin and bio-quercetin. Compared with previous data concerning 
Aspalathin in fermented RB, our extract contained less Aspalathin (0.161g/100g) which was 
comparable the one found in a study (0.17g/100g) (Walters et al., 2017). In another study 
(Joubert et al., 2009) authors also found low levels of Aspalathin in fermented RB extract 
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low quantities of Aspalathin were used by the manufacturers. Moreover, when compared to 
unfermented RBs extract the Aspalathin is much higher with 1.2g/100g, while our extract 
contains about 10 times less Aspalathin 0,161g/100g.   
  
Previous studies have also shown that RB contains number of pharmacologically active 
compounds such as mentioned above which we were also able to quantify. In contrast, the 
content values in the present study are relatively low in comparison to previously analysed hot 
water extracts of RB (Joubert and Beer, 2012), as well as those in (Muller et al., 2016). It seems 
that boiling increased the flavonoid content of RB tea, irrespective of the type (Muller et al., 
2020). Most of the identified compounds in our extract have been shown to attenuate metabolic 
disturbances related to CVDs. PPAG has been shown to be very effective in protecting 
depolarization of the mitochondria and cell apoptosis and against substrate (Dludla et al., 2016). 
Aspalathin and nothofagin have been reported to prevent inflammation and thrombosis by 
suppressing TNF-α, IL-6 and NF-κB in high glucose-induced vascular in HUVECs and mice 
model (Ku et al., 2014). In addition, orientin and iso-orientin are known for their potential to 
maintain vascular barrier integrity through hyperpermeability inhibition (Lee et al., 2014). 
Vitexin has also been shown to exhibit protective properties against cardiac hypertrophy by 
interrupting calcineurin and CaMKII signalling pathways (Lu et al., 2013). Moreover, 
quercetin exhibits antihypertensive properties and alleviates cardiac hypertrophy by increasing 
antioxidant capacity (Chen et al., 2018; Yan et al., 2013).  
  
Our initial Ang-II concentration was based on a previous study that exposed H9c2 cells to Ang-
II at a 100nM concentration that increased hypertrophy and apoptosis (Prathapan et al., 2013). 
However, this concentration and others did not work in our laboratory (Wu et al., 2014; Zhou 
et al., 2014; Li et al., 2017), as it had no impact on cell size. However, we managed to find an 
effect at 20μM Ang-II. We used cell surface area with JC-1 staining as proxy for hypertrophy. 
However, an increase in cell size does not necessarily equate to hypertrophy. Therefore, we 
also assessed hypertrophy signalling pathways. Accumulating data suggest that oxidative stress 
is implicated as one of the key contributing factors in the development of hypertrophy (Fan et 
al., 2019). Ang-II induced ROS activates a wide variety of hypertrophy signalling kinases and 
transcription factors (Maulik and Kumar, 2012). Several studies have demonstrated that Ang-
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Molkentin, 2004; Rohini et al., 2010) these pathways are considered to be important promoters 
of cardiac hypertrophy. In the present study, we demonstrated that Ang-II induced hypertrophy.   
Hypertrophy caused by an up-regulation of the PKB/Akt signalling pathway contains two 
molecular target proteins: GSK-3β and mTOR. Disruption of both PKB/Akt & mTOR could 
explain impaired survival signalling and promote pathological cardiac hypertrophy as 
previously reported by (Aoyagi et al., 2012). Our study demonstrated that Ang-II treatment 
induced phosphorylation of PKB/Akt subsequently increased GSK-3β phosphorylation, which 
in-turn activated an increased cell protein synthetic machinery. Accumulating evidence suggest 
that GSK-3β is well-known as a negative regulator of cardiac hypertrophy that blocks increased 
levels of protein synthesis and expression of hypertrophic genes (Hardt and Sadoshima, 2002). 
Once the active GSK-3β expression is increased in the heart it blocks hypertrophy mediated by 
pressure overload, activated calcineurin and β-adrenergic receptors (Antos et al., 2002). 
Activation of PKB/Akt also resulted in an up-regulation of mTOR, leading to cell enlargement.  
Our findings corroborated previous findings from Wu et al. Their experimental results showed 
that Ang-II induced hypertrophy was mediated by PKB/Akt signalling pathways using H9c2 
cardiomyoblasts (Wu et al., 2014). A study conducted by Chen et al., 2018 also demonstrated 
that Ang-II induced cardiac hypertrophy which was related to activation of GSK-3α/β in 
Neonatal SD rats (1–2 days old).  
  
To our knowledge we show for the first time that RB attenuates hypertrophy in a complex 
model of Ang-II induced hypertrophy in H9c2 cells. From our JC-1 staining data the size of 
H9c2 cells was significantly reduced after treatment with RB compared with the Ang-II treated 
group. Furthermore, we found that RB inhibited Ang-II induced hypertrophy by decreasing the 
PKB/Akt intracellular signalling pathways. Subsequently inhibiting increased expression of 
downstream proteins of PKB/Akt such as GSK-3β and mTOR, which are probable mediator  
for protective effect against Ang-II induced cardiac hypertrophy in H9c2 cells.   
  
Both unfermented and fermented RB have been reported to confer cardioprotection by 
decreasing phosphorylation of PKB/Akt (Pantsi et al., 2011). The decrease in phosphorylation 
of PKB/Akt on serine 473 and threonine 308 by RB extract could be due to the fact that the RB 
extract contains a lot of flavonoids and high polyphenol content level (Schroete et al., 2002). 
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PI3K/Akt to maintain substrate metabolism in the adipose tissue, skeletal & cardiomyoblasts 
(Mazibuko. et al., 2015, Son et al., 2013 & Johnson et al., 2016). Similarly, other plant 
flavonoids such as Vitex and Quercetin can also inhibit Ang-II cardiac hypertrophy and 
apoptosis, with Vitex preventing hypertrophy by inhibiting Calcineurin (Lu et al., 2013). On 
the other hand, quercetin prevent hypertrophy by activating survival pathways which include 
GSK-3ß and Akt (Chen et al., 2019). Recent evidence also shows that Fisetin, a plant 
polyphenol found in apples and cucumber is able to attenuate hypertrophy by activating 
survival signalling pathways such as IGF-IR-PI3K-Akt signaling in H9c2 cells (Chen et al., 
2019). The fact that RB mediates its cardioprotection through PKB/Akt signalling was 
supported by our previous findings, in a model of lipid-induced hepatic insulin resistance using 
palmitate-exposed C3A liver cells, it has also been reported that RB has beneficial health 
effects by modulating survival signalling such as PI3K/Akt and AMPK Pathways 
(MazibukoMbeje et al., 2019). They indicated that treatment with green rooibos extract (GRE) 
significantly increased PI3K/Akt and AMPK phosphorylation while concurrently enhancing 
glucose transporter 2 expression. Another study also reported that green RB extract inhibited 
the proliferation of castrated prostate cancer patients by suppressing the PKB/Akt signalling 
pathway (Huang et al., 2019). These observations suggest that THE /Akt signalling pathway is 
one of the main targets for RB treatments, an effect also observed in our study.   
  
Mitogen-activated protein kinases (MAPKs) have been reported to be involved in primary 
cellular function with regard to both cellular growth and apoptosis. A member of the MAP 
kinase family, ERK1/2, is well-known as a key player in cell proliferation (Su et al., 2015) and 
promoting cardiac hypertrophy (Chen et al., 2018). To confirm the involvement of ERK1/2 as 
one of the growth pathways, we used immunoblotting to assess the phosphorylation of ERK1/2. 
Ang-II increased the phosphorylation of ERK1/2 as compared to the control group, suggesting 
that MAPK/ERK pathway activation had a role in driving the development of cardiac 
hypertrophy in H9c2 cardiomyoblasts. ERK1/2 activation is widely associated with 
antiapoptotic functions but it has also been reported that sustained ERK1/2 activation mediates 
apoptosis (Sun et al., 2012; Wei et al., 2012). Given that activation of the ERK 1/2 signalling 
pathway has been reported can be both pro- and/or anti-apoptotic (Sun et al., 2012). The way 
in which ERK signalling functions can be contradictory as it is believed to be host of both cell 
death and cell survival. Furthermore, this can only be explained and understood through the 
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of MAPKs and the presence of threshold levels for activation explain why robust or sustained 
stimulation of MAPKs is pro-apoptotic (Yue and López, 2020). It has been reported that 
robust ERK activation suppresses the cell cycle via the expression of cell-cycle inhibitor 
proteins, including p21Cip/Waf and p27KIP (Marshall, 1999). On the other hand, weak 
stimulation is anti-apoptotic. Further studies investigating the temporal ordering of 
phosphorylation, early for anti-apoptotic targets and late for pro-apoptotic targets, are required 
to better understand the behaviour of MAPKs (Yue and López, 2020). Our study is in support 
of (Sun et al., 2012) who observed apoptosis mediated by the mitochondria-dependent intrinsic 
apoptotic pathway, ERK signalling pathway and pro-apoptotic Bax. This could also suggest 
that the anti-apoptotic effect linked with RB is responsible for the suppression of Ang-II 
induced ERK1/2 activation. This suggests that ERK activation could also be responsible for 
intracellular ROS generation, which is readily suppressed by RB.   
  
Cardiac hypertrophy is believed to be one of main predictors of continuous heart diseases which 
frequently leads to heart failure associated with alteration in the intracellular calcium handling 
(Wilkins and Molkentin, 2004). Accumulating data suggests that continued pressure overload 
leads to an increased sustained intracellular Ca2+ in cardiomyoblasts (Wang et al., 2012). 
Furthermore, Ca2+ is both a regulatory factor and second messenger and it has been reported to 
play a crucial role in the progression of cardiac hypertrophy (Vicencio et al., 2011). Several 
studies have confirmed that Ca2+ activated kinase, Calcineurin, acts as an important factor in 
promoting the development of hypertrophy (Lu et al., 2013; Heineke & Molkentin, 2006). One 
of the significant signalling pathways responsible for cardiac hypertrophy, calcineurin responds 
to altered calcium is calcineurin–NFAT. Calcineurin is a strong executor of cardiac growth in 
this pathway and it has been reported to be sufficient to promote development of cardiac 
hypertrophy (Molkentin, 2004; Fischer et al., 2013).  In the present study, there was a 
significant increase in calcineurin in hypertrophied cells upon the stimulation of H9c2 with 
Ang-II. The increase in calcineurin is associated with an increase in intracellular Ca2+. RB 
treatment reduced expression of calcineurin. This suggest that the cardioprotection of RB was 
also mediated by inhibition of the Ca2+-calcineurin pathway. The negative regulation of 
calcineurin expression by RB, also inhibited its downstream substrates such as GSK-3ß, ERK 
1/2 and mTOR and thereby blocking Ang-II induced hypertrophy (Molkentin, 2004; Hogan et 
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In addition, high concentrations of intracellular calcium may lead to mitochondrial swelling 
subsequently to a sudden permeability increase to inner mitochondrial membrane, this in turn 
stops the chemiotic gradient across the inner mitochondrial membrane. This leads to 
uncoupling of oxidative phosphorylation and subsequently decreased ATP production and 
increases ROS production (Hunter and Haworth, 1979). Moreover, when the outer 
mitochondrial membrane ruptures it leads to a release of cytochrome-c, a main contributor in 
the initiation of apoptosis (Kroemer et al., 2007). In the present study Ang II-induced apoptosis 
in H9c2 cardiomyoblasts as seen with increased expression of Bax and cleaved caspase-3 and 
subsequent the deceased cell viability.  Transcription factors of anti-apoptotic genes Bcl-2 and 
Bc-xL prevent the release of cytochrome-c and protect cardiac cells from apoptosis (Portt et 
al., 2011). However, Bid and Bax are transcription factors that promote the expression of cell 
death proteins affecting the mitochondrial membrane permeability in a negative way (Raisova 
et al., 2001). Dimmeler et al., 1996 showed that AngII increased apoptosis of human umbilical 
venous endothelial cells. Another study conducted by Condoreli et al., 1999 showed that 
pressure stimulated an increase of apoptosis in cardiomyoblasts and contributed to the 
transition from left ventricular hypertrophy to heart failure, which may be associated with 
upregulation of Bax and reduction of Bcl-2. The present study, confirmed results reported by 
(Condoreli et al., 1999) in their study. We observed an up-regulation of pro-apoptotic mediators 
including Bax and caspase-3, while the anti-apoptotic protein was reduced. The increased 
expression of Bax and caspase-3 was downregulated by RB.   
  
Both apoptosis and hypertrophy can be stimulated by similar factors and there is a cross talk 
between the regulatory mechanisms of the two signalling pathways. Hypertrophy is believed 
to be mediated via increased apoptosis which in turn leads to cardiac fibrosis and cardiac 
muscle damage (Wang et al., 2016). PI3K/Akt is one of the mediators of both apoptosis and 
hypertrophy and its mechanism of action depends on its phosphorylation (Nicholson and 
Anderson, 2002). Our results also showed similar results to those of Chen et al., 2019 who 
observed AngII induced apoptosis by activation of IGF/IR/PI3K/Akt signalling pathways in 
H9C2 cardiomyoblasts and spontaneous hypertensive rats. The PI3K/Akt pathway is important 
for both cell survival when stimulated by Ang-II that influences many other factors that are 
involved in apoptosis, either through direct phosphorylation or transcription regulation 
(Nicholson and Anderson, 2002). It has been documented that Akt, once activated, moves from 
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nucleus, Akt blocks transcription factors that promote the expression of pro-apoptotic genes 
such as caspases, Bax and Bid, and increases the transcription of anti-apoptotic genes such as 
Bcl-2. This suggests that the ability of RB to decrease apoptosis in our study, is mediated by 
direct phosphorylation or by enhancing expression of survival genes. Herein we suggest that 
Bcl2 is the main regulatory network used by which RB protect the cardiomyocyte against 
AngII-induced apoptosis. This further suggests that the Bcl-2 family proteins were directly 
regulated by RB and may have an effect on mitochondrial membrane pore formation, leading 
to the blockage of cytochrome c release, causing caspase-3 inhibition of the intrinsic apoptotic 
pathway (Sun et al., 2012). Activation of the caspase-3 was inhibited by RB in our study.  
  
Comparable results were observed in H9c2 cells exposed to chronic hyperglycaemia. 
Treatment with aspalathin, a major phenolic compound in RB extract, was seen to protect 
cardiomyoblasts against Fas ligand-induced apoptosis by activating the Igf-PI3K-Akt 
prosurvival pathway by increasing expression of Bcl-2 (Johnson et al., 2016). An alteration in 
the Bcl-2/Bax ratio is most likely to lead to increased mitochondrial depolarization, 
subsequently leading to a release of cytochrome-c, which is an important molecule to promote 
development of apoptosis. We observed that Ang-II resulted in a decrease in Bcl-2/Bax ratio, 
thus, an increase in apoptosis. However, treatment with RB reversed induced apoptosis by 
increasing the Bcl-2/Bax ratio.  These observations are consistent with TUNEL staining and 
western blotting results for Bax and Bcl-2 found in isolated heart cells of diabetic mice using 
fermented rooibos extract (Dludla et al., 2017). These findings therefore strongly suggest that 
RB protects against oxidative stress-induced myocardial apoptosis.   
  
Previous studies have reported that protection provided by RB extract is most likely to be 
attributed to an alteration of apoptotic promotors (Pantsi et al., 2011). Studies also showed that 
Quercetin, a flavonol, alters apoptotic signalling pathways by maintaining mitochondrial 
membrane potential, down-regulating increased expression of Bax, activating Bcl-2 and further 
altering increased expression of caspase-3 (Choel et al., 2009; Hsu et al., 2006). Several studies 
also showed that treatment with Rutin, another flavonoid, offered anti-apoptotic effect by 
altering the increased expression of caspase-3 and upregulating Bcl-2 levels (Jeong et al., 2009; 
Gong et al., 2010). Similarly, a study by (Pantsi et al., 2011b; Dludla et al., 2016), showed a 
significant decrease in caspase-3 in the RB treated group. Therefore, our results agree with the 
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Our study further suggests that the apoptosis that develop during Ang-II treatment associated 
with p38 MAPK. Besides the fact that p38 is well-known for its role in the cellular stress 
response and inflammation, p38 MAPK has also been implicated in promoting regulated cell 
death (Cuenda and Rousseau, 2007). P38, the stress-response protein, a member of MAPK 
implicated in execution of apoptosis was also up-regulated after cells were treated with Ang-II 
(Zhou et al., 2014).  Ang-II induced increase in p38 MAPK phosphorylation has been identified 
to be crucial in cellular responses such as inflammatory, apoptosis (Bagchi et al., 2017) also 
responsible for mediating the development of other CVDs such hypertrophy (Chan et al., 2005). 
As reported by (Prathapan et al., 2013), our experiments have also showed that Ang II induced 
apoptosis in H9c2 and the mechanism of action might be mediated by the activation of p38 
MAPK and other apoptotic executors. Normally, stimulation of p38 MAPK is executed during 
its phosphorylated state. For us to confirm whether the anti-apoptotic effects of RB had 
anything to do with p38 MAPK, we used specific antibody to look at phosphorylated and total 
p38 MAPK in Ang II- exposed H9c2 cells. We observed a significant decrease in 
phosphorylation of P38 after co-treatment with RB. For this reason, the anti-apoptotic action 
of RB may also be dependent on its ability to inhibit increased phosphorylation of p38 MAPK. 
The mechanism of action of RB’s anti-apoptotic effect is assumed to be by blocking 
ROSdependent p38 signalling pathways (Zhou et al., 2014). Subsequent increase of p38 
MAPK phosphorylation led to an increase in expression of pro-apoptotic protein; Bax, and 
caspase-3. However, RB inhibited all the pro-apoptotic proteins and down-regulated Bcl-2 an 
antiapoptotic protein.   
  
Moreover, increased expression of Bcl-2 or Bcl-xL has been shown to ameliorate 
stressmediated accumulation of p38 at the mitochondria and thereby prevent apoptosis 
(Perfettini et al., 2005). On the other hand, ROS is suggested to be another possible link 
between p38 MAPK signalling and the intrinsic pathway. Mitochondrial ROS may cause DNA 
damage and protein oxidation, subsequently activating the redox-sensitive kinase p38 MAPK 
to promote host cell death by apoptosis (Jia et al., 2007).  
  
To gain insight into RB effects and understand some mechanism of action on oxidative stress 
amelioration in Ang-II-induced hypertrophy and apoptosis in H9c2 cells, we investigated 
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RB using JC-1 staining. JC-1 dye in normal cells becomes more concentrated in the 
mitochondrial matrix by emitting a red fluorescence aggregates due to existence of 
electrochemical potential gradient. Any alteration in the mitochondrial membrane potential 
prevents JC-1 from accumulation in the mitochondria, thus, it gets dispersed all over the cell 
resulting in monomers emitting green fluorescence. Our data shows more JC-1 aggregates (red 
fluorescence) in healthy control cells revealing intact mitochondria. Ang-II treated cells 
displayed a depolarized membrane potential which was evident from significantly increased, 
formation of JC-1 monomers (green fluorescence) in hypertrophied cells. RB maintained the 
membrane potential, which was associated with increased amount of red fluorescence. The 
significant increase in mitochondrial membrane potential observed with RB in our Ang-II 
treated H9c2 cells, was supported by observing increased cell viability. Therefore, we 
demonstrated the mitochondrial protective effect of RB extract on Ang-II-induced hypertrophy 
and apoptosis. This suggests that RB treatment can effectively prevent Ang-II-induce 
mitochondrial damage such as depolarization of mitochondrial membrane potential. Thus, the 
treatment with RB can prevent loss of mitochondrial structure and functional integrity in the 
cell culture model.  
  
We also found that the ATP content was significantly increased with RB and AngII cotreatment 
of H9c2 cardiomyoblasts, this was supported by the data obtained for mitochondrial membrane 
potential studies. These findings suggest that mitochondrial dysfunction was restored by RB, 
illustrated by maintenance in mitochondrial membrane potential and greater capacity to 
improve ATP activity. RB-treated cells are thought to maintain their mitochondrial membrane 
potential through less demand for ATP consumption in their mitochondria. Similarly, an 
increase in mitochondrial membrane potential was also observed in 3T3-Li preadipocytes after 
48 hrs of treatment with green RB extract and fermented RB extract also illustrated by an 
increase in percentage cellular ATP content. (Hattingh et al., 2019; Pantsi et al., 2011b).  
Furthermore, our study demonstrated that cardiac hypertrophy was associated with decreased 
mitochondrial respiratory chain complex IV and V. The decrease in the expression of complex 
IV has been reported to have a direct influence on oxygen consumption rate and electron 
transport chain in vivo (Sohal, 1993; Schwarze et al., 1998). This decrease in complex IV is 
also most likely to increases the upstream carriers in a decreased state, which in turn increase 
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(Ferguson et al., 2005). There are several mechanisms proposed to explain hypertrophy/ 
apoptosis related complex IV activity. Firstly, adding to the fact that complex IV causes an 
increase in generation of ROS, the observed decrease in expression of complex IV could also 
be directly subsequent to increased ROS production (Ferguson et al., 2005). Mitochondria are 
both sources and targets of ROS, and production of H2O2 by the mitochondria might be 
increased as a result of cardiac hypertrophy-associated mitochondrial dysfunction.   
  
A second possible explanation for the decreased complex IV expression could be damage in 
the subunits encoded by mitochondrial DNA. Mitochondrial DNA is known to be the first 
target of oxidative damage because it is very close to the ETS and could also result from the 
absence of histone-like protein protective layer (Caron et al., 1979; Clayton, 1982). In addition, 
there is the possibility of a loss of cytochrome-c because cytochrome-c interact with both 
complex III and IV. Therefore, loss of cytochrome-c indicate that apoptosis may have played 
a part (Fosslien, 2003). However, our results showed no significant difference in mitochondrial 
complex II and III after incubation with RB as compared to Ang-II-treated group. In addition, 
Pereira et al., 2019, also observed similar results by failing to show significant difference in 
mitochondrial complex III after incubation with different concentrations of mitogen-activated 
protein kinase MEK inhibitors. However, in another study using a rabbit model of neonatal 
pressure overload induced hypertrophy, they observed a decline in mitochondrial complex I 
and III activities during compensated hypertrophy. In addition, this was accompanied by a 
decrease in the mitochondria ROS and oxidative damage that only manifested itself after 
progression to heart failure (Griffiths et al., 2010). RB improved mitochondrial function by 
restoring complex IV expression after it was negatively affected by Ang-II. Previous studies 
suggest that ROS production at complex II is believed to be low at physiological concentrations 
of succinate. Therefore, this supports the notion that complex II is not the main source of ROS 
involved in hypertrophy and apoptosis (Stoll et al., 2018; Zorov et al., 2014). We also observed 
no significant difference between Ang-II-treated and RB treated groups.  
  
The decrease in the complex V expression may lead to a decrease in the ability of the heart to 
meet energy demands. The demand of energy being weighed down by energy supply is then 
followed by a moderate but continuous decrease in the activity of mitochondrial respiration, 
subsequently diminishes the rate at which the ATP is generated (Jonckheere et al., 2012; 
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in Ang-II treated group. However, to compensate for the loss of ATP during this abnormal 
enlargement of the cardiomyoblasts, the mitochondria have to increase the production of ATP 
and RB seemed to significantly increases ATP content as needed (Stoll et al., 2016). The 
increase in complex V after treatment with RB in hypertrophic cardiomyoblasts, could mean 
that RB increased the capacity of the mitochondrial oxidative phosphorylation of the cells 
during hypertrophy. However, we did not measure mitochondrial respiratory capacity or 
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Chapter 5: Conclusions  
  
Our cold water fermented RB extract conferred cardioprotection against the toxic effects of 
Ang-II treated H9c2 cells. RB achieved this effect by reducing hypertrophy and apoptosis, 
improving mitochondrial membrane potential, restoring expression of complex IV and V, and 
enhancing ATP activity. These effects of RB were further supported by inhibiting the 
phosphorylation of hypertrophy signalling pathways including GSK-3ß, ERK1/2, PKB/Akt, 
Calcineurin and mTOR, while reducing expression of Bax, cleaved caspase-3, and p38 and 
increasing Bcl-2. Our study is the first to demonstrate RB-induced cardioprotection in a model 
of both hypertrophy and apoptosis induced by Ang-II with clear underlying mechanisms.  
 
Figure 43: Summary of Anti-hypertrophic and anti-apoptotic effect of RB. This figure 
shows a summary of signalling pathways RB used to inhibit Ang-II induced-cardiac 
hypertrophy and apoptosis.  
  
  





 105  
    
6.0 Novelty and significance  
  
We established a new model of both hypertrophy and apoptosis induced by Ang-II in H9c2 
cardiomyoblasts.  
  
RB is widely used against heart diseases in the traditional system of medicine. However, its 
cardioprotective properties related to hypertrophy have not been evaluated. Therefore, our 
study is the first to give evidence of the cardioprotective effect of RB in a model of Ang-II 
induced hypertrophy.  
7.0 Limitations  
  
Our experiments had some limitations. In this study we could not detect complex I, because the 
band was too faint to analyse. Moreover, during fractionation we could not get enough proteins 
from the nucleus which made it impossible for us to observe translocation of NFAT from the 
cytosol to the nucleus during hypertrophy. In our attempt to yield more protein in the nuclear 
fraction we added different concentrations of SDS and NP-40. However, probing with actin 
and histone for cytosol and nucleus, respectively, we were unable to obtain a pure nuclear 
sample.  
  
For our aconitase measurement the assay provided inconsistent readings i.e. extreme 
differences among the biological repeats, which made it difficult to determine aconitase activity. 
Therefore, the data of the aconitase assay could not be used as an indication of mitochondrial 
stress. This method was a kinetic assay that was time dependent and more optimisation is 
needed. We also measured whole cell lysates and therefore, the mitochondria concentration 
might be very low. Thus, in the future we plan to use a mitochondrial isolation kit to directly 





 106  
    
8.0 Future directions  
  
We will be looking at mitochondrial function with high-resolution respirometer (Oroboros®), 
as this will allow us to comprehensively assess mitochondrial respiratory pathways and the 
effects of RB on them, to confer cardioprotection. This is important, as mitochondrial 
respiratory pathways are central to the development of cardiac hypertrophy and apoptosis. We 
would also like to confirm hypertrophy with other hypertrophic markers such as NFAT 
translocation (from cytosol to nucleus) or GATA4 expression and to further look at mRNA 
levels of hypertrophic genes like BNP, ANP and ßMHC. We are also planning measure SOD 
and CAT, the two scavenging enzymes and MitoSox staining a novel fluorogenic dye that is 
specifically used to target the mitochondrial superoxide in live cells. We will also measure 
NOX activity to see generation and involvement of mitochondrial ROS. We will measure NOX 
using total ROS detection kit (Enzo, US) following the manufacture’s protocol. The 
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10.0 Appendix  
  
Herewith the western blot results of each antibody used in 3 biological repeats. On the left side 
is the chemiluminescence blot and corresponding the membrane on the right (to account for 
the protein loading).  
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Total GSK Blots  
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Phosphorylated PKB blots  
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